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ABSTRACT

NOVEL HYBRID ANALOGS OF ESTRONE ORIGIN EXHIBITS CYTOTOXIC
EFFECTS AGAINST EGFR-DEPENDENT CANCERS

FELIX ACHEAMPONG

2019

Cancer is second only to cardiovascular illnesses as the deadliest human disease globally.
Currently, non-small cell lung cancer (NSCLC) and triple negative breast carcinoma
(TNBC) are the most frequent types of cancer and have the highest mortalities. Epidermal
growth factor receptor (EGFR), a central regulator of tumor progression, is frequently
overexpressed in both cancers and is a key clinical target for therapeutic intervention.
Natural products and their synthetic analogs have been utilized as EGFR tyrosine kinase
inhibitors (TKIs) with potent antitumor effects. However, acquired resistance limits the
long-term efficacy of these drugs. Estrone has been used as a scaffold in some studies
where pharmacophores with antitumor properties were introduced to generate lead
candidates with improved efficacy and safety. In our research group, estrone is employed
as a starting material to synthesize novel hybrid analogs. Many of our estrone analogs,
especially those bearing cucurbitacin pharmacophores have been documented to exhibit

xvii

potent cytotoxic effects against distinct cancers. However, these hybrid analogs have never
been explored as potential agents targeting EGFR-dependent cancers. Here, we describe
the cytotoxic effects of novel estrone analogs: a hybrid of estrone base-scaffold and
modified cucurbitacin (MMA series) or triazole (Fz series) pharmacophores as potent
agents against EGFR-dependent cancers, viz. NSCLC (NCIH226) and TNBC (MDA-MB231, MDA-MB-468) tumor models. Molecular docking studies were carried out with
OpenEye software. The MTT cell viability and trypan blue stain assays were used to
perform cytotoxicity studies. Morphological changes and cell cycle arrest were carried out
by microscopy and flow cytometric techniques, respectively. Annexin V assay was utilized
to evaluate initial apoptosis induction in all cells and In-cell western assay was used to
detect protein expression levels associated with mitochondrial apoptosis, cell cycle, EGFR
and its downstream AKT and ERK1/2 pathways. Molecular docking studies revealed that
most estrone analogs exhibited improved potency and binding compared to the positive
controls, erlotinib and sorafenib when docked against the EGFR kinase-domain (pdb
codes: 2ITW, 1M17). Subsequently, several estrone analogs exhibited significant cytotoxic
effects against the different cancer cell lines in vitro. Notably, MMA307 and MM320
recorded lower IC50 molarities of 2.88 ± 0.21 and 9.68 ± 0.24 µM compared to the positive
control, sorafenib, IC50 value of 20.62 ± 1.32 µM in NCIH226 cells. Similarly,
administration of MMA307 and MMA321 to MDA-MB-468 cells yielded potent IC50
concentrations of 0.85 ± 0.00 and 0.56 μM ± 0.01 μM, respectively, when compared to
sorafenib, IC50 value of 10.09 ± 0.68 μM. Furthermore, Fz25 recorded IC50 dose of 8.13 ±
0.15 μM in MDA-MB-231 cell lines when compared to sorafenib, 12.21 ± 0.96 μM.
Treatment with the MMA307 and MMA320 resulted in downregulation of Dyrk1B (dual-

xviii

specificity tyrosine phosphorylation-regulated kinase B), cyclin D1 and concomitant
upregulation of phospho-cyclin D1 and p21waf1/cip1 contributing to cell cycle arrest in the
G1 phase. Also, downregulation of EGFR and phospho-EGFR levels as well as suppression
of activated MAP kinase signaling proteins-phospho-B-Raf, phospho-MEK1/2 and
phospho-ERK1/2 were observed after NCIH226 cells were exposed to estrone analogs.
Similarly, MMA307 and MMA321 downregulated cyclin D1 expression levels resulting
in G1 phase cell cycle arrest in MDA-MB-468 cells. Also, these compounds halted the
MAPK and AKT signaling pathways due to their ability to downregulate EGFR and
activated EGFR expressions. Moreover, mitochondrial apoptosis was induced in the TNBC
model, MDA-MB-468, upon MMA307 and MMA321 exposures. In a different study,
treatment of MDA-MB-231 cells with Fz25 induced mitochondrial apoptosis and
contributed to the G1 phase of cell cycle arrest due to decreased expressions of cyclin D1
and Dyrk1B. Interestingly, this compound impacted the MAPK and AKT signaling
pathways due to its ability to decrease EGFR and activated EGFR expressions. To
conclude, the present study is the first to report on the cytotoxic potential of novel estrone
analogs and provide evidence that MMA307, MMA320, MMA321 and Fz25 are
promising novel lead compounds. Further investigations are needed to develop these potent
compounds as the next generation anti-EGFR therapies for treating serious EGFRdependent lung and breast cancers.
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Chapter 1

1.1

Introduction and Background

Cancer is a complex genetic disease or group of diseases characterized by the
uncontrolled growth and spread of nonhealthy cells. The spread of malignant cells (a
phenomenon called metastasis) is responsible for patient’s death. The disease incidence
and mortality are rapidly growing globally; ageing, unhealthy lifestyle, family history,
chemical and environmental factors, and genetic susceptibility are the major risk
factors proposed for developing cancer. In the past cancers were classified based on
histology and primary site (location in the body), therefore, six major categories,
namely carcinoma, sarcoma, myeloma, leukemia, lymphoma, and mixed types have
been established based on histology alone. According to primary site lung, breast,
prostate, liver, stomach, head and neck, etc. cancers have all been identified (Figure
1.1).
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Figure 0.1. Cancer incidence and mortality. Lung and breast cancers have the highest
incidence in both males and females. Lung cancer has the highest mortality rate followed
by stomach, liver and breast cancers in both sexes. However, in females, breast cancer has
the highest mortality. Data adapted from Bray et al., 2018.
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1.2

Lung and Breast cancers as serious illnesses worldwide

Lung cancer is the most common cause of cancer mortality worldwide with an
estimated 1.8 million deaths yearly (Bray et al., 2018). Also, it accounts for more than
a quarter of all cancer-related deaths (Siegel et al., 2017). Usually, lung cancer is
classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
“Small cell or non-small cell” refers to the type of cell within the lung where the cancer
originated. About 85% of lung cancer cases are NSCLC (the most frequent type), of
which lung adenocarcinoma and lung squamous cell carcinoma are the most common
subtypes (Herbst et al., 2018). Large cell carcinoma is the less common type. The
remaining 15% represent SCLC cases, four subtypes have been identified: oat cell
carcinoma, small cell carcinoma of the intermediate cell type, combined oat cell
carcinoma, and undifferentiated carcinoma of the small cell type (Nomori et al., 1986).
Many lung cancer patients have locally advanced disease at the time of initial diagnosis
and about 7-10% of patients present with brain metastases (Ali et al., 2013). The key
cause of lung cancer is attributed to tobacco smoking, accounting for more than 80%
of the cases in countries where smoking is common (Alberg et al., 2013). However,
nonsmokers also develop lung cancer when exposed to conditions like second-hand
smoking, pollution and occupational carcinogens, and with inherited genetic
susceptibility (Herbst et al., 2018).

Breast cancer has the second highest incidence rate globally after lung cancer and
accounts for the fourth highest mortality after lung, stomach and liver cancers. In
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females, breast cancer records the most deaths every year (Bray et al., 2018). This
disease is usually classified into four subtypes, luminal A-like (ER-positive (ER+)
and/or PR-positive (PR+), HER2-negative (HER2–)), luminal B-like (ER+ and/or PR+,
HER2-positive (HER2+)) HER2-enriched (ER-negative (ER–)/PR-negative (PR–
)/HER2+), and triple-negative breast cancer (TNBC; ER–/PR–/HER2–) based on
immunohistochemistry studies on estrogen receptor (ER), progesterone receptor (PR),
and human epidermal growth factor receptor-2 (HER2) (Ma et al., 2017). The luminal
A-like subtype is the most frequently occurring subtype and accounts for 62–67% of
invasive cases; TNBC is the second most common subtype and accounts for 10–25%
of invasive cases and is more aggressive with poor prognosis (Dai et al., 2015;
Uscanga-Perales et al., 2016; Lee and Djamgoz, 2018). In comparison to non-TNBC
(luminal A-like, luminal B-like and HER2-enriched) tumors, TNBC tumors are
frequently larger and less differentiated and are almost 2.5-fold more likely to
metastasize within five years of diagnosis (Uscanga-Perales et al., 2016). Moreover,
TNBC metastasizes preferentially to the viscera and nervous system in contrast to nonTNBC which spreads mostly to the bone. Also, it is more often associated with breast
cancer type 1 (BRCA1) mutation and to a less extent, BRCA2 mutations (Podo et al.,
2016). In the past, TNBC was subclassified into six types based on gene expression
profiling (Lehmann et al., 2011), however, currently, these have been narrowed down
or refined into four subclasses: basal-like 1 (BL1), basal-like 2 (BL2), luminal
androgen receptor (LAR) and mesenchymal (M) (Lehmann et al., 2016). These TNBC
subtypes are known to activate different signaling pathways. BL1 shows elevated
expression of Ki67, BL2 presents with elevated expression of TP63, MET and activate
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glycolysis and gluconeogenetic pathways. On the other hand, LAR increases the
expression of androgen receptors and M activates mTOR and angiogenesis signaling
(Uscanga-Perales et al., 2016). It must be noted that racial ancestry, gestation, lack of
lactation, high body mass index, metabolic syndrome, type 2 diabetes, obesity and/or
insulin resistance are all risk factors to developing the TNBC phenotype (Ma et al.,
2017; Kim et al., 2015).

Recent breakthroughs in molecular and cellular biology have allowed the use of
biomarkers or genetic markers to classify cancers into distinct phenotypes and to
identify druggable targets. In the past 30 years, important molecular markers associated
with several mechanisms including proliferation, growth, survival, angiogenesis, cell
death, metastasis, etc. pathways have all been reported for both NSCLC and TNBC.
The most reported and targeted biomarker is the epidermal growth factor receptor
(EGFR), a central regulator of tumor progression.
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1.3

Key molecular drivers associated with NSCLC and TNBC progression

NSCLC and TNBC are molecularly heterogeneous disease and understanding their biology
is crucial for the development of effective therapies. Molecular profiling studies have led
to the identification of driver mutations in more than 50% of patients with NSCLC
(Baumgart, 2015) and an almost equal number in TNBC cases (Annunziato et al., 2019).
From variant mutation analyses, alterations in the Kirsten rat sarcoma (KRAS), BRAF and
EGFR genes have been associated with NSCLC initiation and represent attractive targets
for therapeutic intervention. In TNBC, mutations in BRCA1/2 (germLine), TP53, MYC
and driver-genes associated with growth pathways like EGFR, MEK have been reported
(Santoro et al., 2019; Sabatier et al., 2019). KRAS is frequently mutated in NSCLC and is
found in approximately 32.2% of patient cases (Ha et al., 2015; Anguera and Majem,
2018). The RAS genes encode for membrane-bound GTP binding proteins, which are part
of the RAS/MAPK signaling pathway linking EGFR activation to cell proliferation and
survival. Mutations in the KRAS gene tend to be mutually exclusive from EGFR mutations
and ALK translocations and are believed to be a negative prognostic factor for survival
(Baumgart, 2015). Also, BRAF, a downstream mediator of KRAS, activates the MAP
kinase pathway involved in cell proliferation. Mutations in BRAF are found in about 4%
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of patients with NSCLC adenocarcinoma; specifically, BRAFV600E represents about
56.7% of the identified mutations within the gene (Anguera and Majem, 2018).

On the other hand, TNBC tumors show different mutation characteristics compared to
NSCLC tumors. Loss of BRCA1/2, because of either germLine or somatic mutations or
due to promoter hypermethylation, has been suggested in about 50% of patient cases
(Garrido-Castro et al., 2019). BRCA1/2 genes are crucial for error-free repair of DNA
double-strand breaks via homologous recombination, and loss of or reduced expression of
these genes results in elevated levels of chromosomal instability and a specific mutator
phenotype. Also, mutations in TP53 tumor suppressor gene, occur in more than 80% of
TNBC cases (Bae et al., 2018). This gene is frequently mutated in basal-like TNBC, with
nonsense and frameshift mutations enriched. TP53 regulates several genes and is involved
in DNA-damage response and cell-cycle regulation mechanisms. In addition, nextgeneration sequencing (NGS) data shows that MYC amplification was noted in about 26%
of TNBC group (Shi et al., 2018). MYC (an oncogenic transcription factor) regulates the
transcriptional activity of multiple genes involved in cell proliferation, metabolism, and
survival. It is suggested that MYC conjoins with RAS–MAPK to drive tumor progression
in TNBC cell lines, and MEK inhibition potently inhibits tumor growth in MYCoverexpressed breast cancer (Balko et al., 2014).

EGFR is expressed on the cell surface of a substantial percentage of NSCLC and TNBC
cells. This member of the receptor tyrosine kinase class of receptors is important in
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transducing extracellular signals from the cell surface to the cell interior, mediating crucial
processes such as cell proliferation, differentiation, migration, and apoptosis. Dysregulated
expression of these receptors can lead to the aberration of homeostatic cellular processes,
resulting in malignant transformation of cells. Activating EGFR mutations have been
reported in cancers such as NSCLC, TNBC and head and neck cancers. These EGFR
mutations are predictive of response to anti-EGFR therapy (Teng et al., 2011). These
mutations often are associated with poor prognosis. In NSCLC, EGFR overexpression or
alterations in the kinase domain have been observed in 40-80% of primary cases and
around 88% in patients with metastatic disease (Sim et al., 2018). When compared to
KRAS, EGFR mutations in smokers and non-smokers varies irrespective of racial
background. Non-smokers tend to have higher expression of somatic EGFR mutations
compared to smokers. It is noteworthy to mention that, among the identified EGFR kinase
domain mutations, over 90% appear as short in-frame deletions in exon 19 or as point
mutations in exon 18-21, the latter resulting in arginine replacing leucine at codon 858
(L858R) (Jorge et al., 2014). Thus, patients with NSCLC are classified as either being
EGFR mutants (having mutations within the kinase domain) or EGFR wild-type
(exhibiting EGFR overexpression or amplification). Based on this, different treatments are
recommended for the unique NSCLC patient population.

Though TNBC lacks the expressions of ER, PR, and HER2, studies have revealed that
EGFR is highly expressed or amplified in TNBC (50-75% of cases), especially in the
advanced state (Dent et al., 2007). According to Teng et al., 2011, TNBC cells harbor
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EGFR mutations, including exon 19 deletions, inversions and exon 21 missense
substitutions. However, TNBC patients have not been well classified based on EGFR status
as found in the case of NSCLC. The same study predicted that these EGFR mutations may
sensitize TNBC towards tyrosine kinase inhibitors (TKIs) and may enhance the potential
use of anti-EGFR therapy.

1.3.1

Role of EGFR and its downstream pathways in tumor progression

EGFR is a receptor tyrosine kinase (RTK) and a member of the HER family of receptors
composed of EGFR/HER1/ERB1, HER2/ERB2, HER3/ERB3, and HER4/ERB4. There
are 11 different growth factors associated with the receptors which can be broadly divided
into those that specifically bind with EGFR (EGF, TGF-α, Amphiregulin), those that bind
with EGFR and HER4 (BTC, HB-EGF, Epidermal regulators), and those that bind with
HER3 and HER4 (Neuregulin). EGFR structurally consists of a C-terminus intracellular
region that possesses the kinase activity, an N-terminus extracellular ligand-binding site,
and a hydrophobic transmembrane domain (Liu et al., 2017). Downstream signaling from
these receptors proceeds via tyrosine phosphorylation which activates multiple
downstream signaling pathways including RAS/MAPK and PI3K/Akt cascades that lead
to transcriptional regulation of genes involved in cell proliferation, motility, and survival
(Figure 1.2). Phosphorylation on serine and threonine residues within the kinase domain
leads to its sequestering and degradation (Liu et al., 2017).
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1.3.1.1 Mitogen-activated protein (MAPK) kinase signaling

The mitogen-activated protein kinases (MAPK) pathway, often known as a cascade of
protein kinases, composed of RAS, RAF, mitogen-activated protein/extracellular signalregulated kinase (MEK) and the extracellular signal-regulated kinase (ERK), is a highly
conserved signal transduction pathway in all eukaryotic cells. The MAPK pathway is one
of the best-characterized signaling cascades that regulates a variety of normal cellular
functions, such as cell proliferation, differentiation, survival and apoptosis, by transmitting
signals from upstream extracellular growth factors to diverse downstream effectors located
in the nucleus (Molina and Adjei, 2006). The RAS/MAPK pathway is initiated through the
promotion of Ras binding to guanosine triphosphate (GTP), which in turn activates RAF
kinases MAPK/extracellular signal-regulated kinases (MEK), and ERK. Activated ERK is
thought to translocate into the nucleus, where it phosphorylates and activates numerous
targets such as elk-1, c-jun, fos, etc. involved in cell cycle progression and proliferation
(MacCorkle and Tan, 2005). Moreover, activated ERK phosphorylates multiple substrates
ranging from kinases to transcription factors and is positioned as a key kinase that controls
multiple cellular processes due to its rather broad nature of substrate recognition.

1.3.1.2 Phosphatidylinositol-3 kinase (PI3K) signaling

Upon EGFR autophosphorylation on tyrosine residues, PI3K is recruited to the membrane
by directly binding to phosphotyrosine consensus residues of EGF receptors or by binding
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to adaptors through p85 regulatory subunit. PI3K activation leads to the production of the
second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3) from the substrate
phosphatidylinositol-4,4-bisphosphate. PIP3 then recruits a subset of signaling proteins
with pleckstrin homology (PH) domains to the membrane, including protein
serine/threonine kinase-3′-phosphoinositide-dependent kinase 1 (PDK1) and Akt/protein
kinase B (PKB) (Portia et al., 2014). The constitutively active PDK1 then induces the
phosphorylation of AKT kinase domain at Thr308 and Ser473 at the carboxyl-terminal
position to initiate the complete activation of AKT. Subsequently, AKT can indirectly
inhibit (phosphorylate) tuberous sclerosis complex 1/2 (TSC1/2 - hamartin and tuberin),
thereby activating the mammalian target of rapamycin (mTOR) signaling. mTOR activity
is carried out by two distinct complexes: mTORC1 and mTORC2 that act downstream and
upstream of AKT, respectively. As a key signaling node, the mTORC1 complex contains
the regulatory protein, raptor which regulates the phosphorylation of p70S6 kinase and 4Ebinding protein 1 (4EBP1), and controls their downstream functions in protein translation,
cell growth, and cell proliferation (Fruman et al., 2017). Also, mTORC2 is known to
activate AKT, thereby promoting cell proliferation and survival. Previous research
suggested that malfunctioning of the EGFR-RAS-MAPK and EGFR-Akt-mTOR signaling
axes play important roles in NSCLC and TNBC progression. Particularly, overexpression
of EGFR and phosphorylated EGFR as well as overexpression of phosphorylated MAPK,
AKT and mTOR is documented in the advanced stages both cancers (Ignacio et al., 2018;
Chen and Costa, 2018; Foidart et al., 2019; Liu et al., 2017; Sato et al., 2018). It is also
reported that increased expression of phosphorylated mTOR and MAPK leads to G1 to S-
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phase cell cycle entry by modulating cyclin and cyclin-dependent kinases expression
(Foidart et al., 2019; Nagata et al., 2010; Gridelli et al., 2008).

1.3.1.3 G1 phase cell cycle progression

The increased expression of cyclins, particularly cyclin D, activates cyclin-dependent
kinase (CDK) 4/6 activity and inactivates retinoblastoma tumor suppressor (Rb) activity,
resulting in the activation of the transcription factor E2F and the upregulation of target
genes that are essential for progressing from the G1 to S phase of the cell cycle. On the
other hand, the expression levels of the cyclin-dependent kinase inhibitors, p21cip1 and
p27kip1, are decreased when the RAS/MAPK and PI3K/AKT pathways are activated (Nagata
et al., 2010). Dyrk1B-(dual-specificity tyrosine phosphorylation-regulated kinase B), a G1S phase checkpoint kinase, is amplified or overexpressed in certain human cancers
signifying that it may be an oncogene (Ashford et al., 2014; Gao et al., 2013). It is thought
to arrest damage tumors in the G0/G1 phase to allow their repair in the quiescent state while
maintaining the clonogenicity of tumors via mediating cyclin D1 turnover and stabilizing
p21cip1. Gao et al., 2013, suggested that increased expression of activated MAPK positively
correlated with Dyrk1B expression in NSCLC and ovarian cancers.
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Figure 0.2. EGFR signaling pathway. EGFR is a receptor protein that spans the cell
membrane. Binding of EGF to the receptor leads to the formation of an asymmetric dimer.
Autophosphorylation of tyrosine residues activates the RAS-RAF-MAPK and PI3K-AKT
pathways. Figure adapted from Liu et al, 2017.
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1.3.1.4 Apoptosis pathways

Activation of RAS/MAPK and PI3K/AKT/mTOR pathways in NSCLC and TNBC tumors
is suggested to override apoptosis by activating antiapoptotic proteins and suppressing
proapoptotic proteins. Apoptosis occurs through two distinct molecular pathways, which
are regulated by caspases. The intrinsic or mitochondrial pathway is activated by
intracellular events and depends on the release of pro-apoptotic and anti-apoptotic factors
from the mitochondria, such as the B-cell lymphoma 2 (Bcl-2) family proteins, cytochrome
c and APAF-1, among others. The released cytochrome c from the mitochondrial to the
cytoplasm binds and activate apoptotic protease activating factor 1 (APAF-1). Activated
APAF-1 apoptosome then activates caspase-9 which subsequently activates caspase-3
(Winter et al., 2014). The extrinsic pathway is initiated by the binding of an extracellular
death ligand to its cell-surface death receptor. This leads to the activation of caspase 8,
which also activates the effector caspase 3 (Winter et al., 2014). The extrinsic pathway can
crosstalk with the intrinsic pathway through caspase-8-mediated cleavage of BID (a
member of the Bcl2 family of proteins) (Billen et al., 2008). Finally, caspase-3 cleaves and
inactivates PARP-poly (ADP-ribose) polymerase-which is important for damaged DNA
repair, thereby inducing apoptosis (Figure 1.3) (Soldani and Scovassi, 2002).

EGFR and its downstream pathways represent attractive therapeutic targets, and the
inhibition of multiple pathways is likely to prevent the compensatory effect of the feedback
loop which is a major issue for molecular targeted therapy in many types of cancer.
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Figure 0.3 Apoptosis pathways. Apoptosis can occur through the intrinsic (mitochondrial)
pathway or extrinsic pathway. Intrinsic apoptosis is characterized by cytochrome c release,
apoptosome formation by APAF1 and activation of caspase 9. Extrinsic mechanism occurs
via ligands binding to the death receptor and activating caspase 8. Both mechanisms
crosstalk through truncation of the protein called BID. Figure adapted from Manoto et al,
2017.
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1.4

Therapies for NSCLC and TNBC

Most patients with NSCLC or TNBC are diagnosed with metastatic disease. In NSCLC,
the five-year overall survival in the advanced stage of the disease is 5% (Baxevanos and
Mountzios, 2018) whereas in TNBC the 5-year survival in advanced stage tends to be about
22% (American Cancer Society, 2019). Chemotherapy has been the mainstay of treatment
in patients with metastatic NSCLC or TNBC for a long time and since no cure can be
achieved, it is given with palliative intent. It must be mentioned that treatments such as
surgery, radiation, immunotherapy, among others are also recommended for NSCLC and
TNBC patients.

1.4.1

Chemotherapy as a treatment modality for TNBC and NSCLC-success and
challenges

1.4.1.1 Chemotherapy as a superior treatment for wild-type NSCLC

Chemotherapy is the application of chemicals or drugs to kill cancer cells, and its effects
are systemic. In NSCLC, chemotherapy is the recommended first line treatment for patients
with overexpressed (wild-type) EFGR whereas targeted agents such as EGFR-TKIs are
used as second- or third-line agents. However, the treatment order is reversed for NSCLC
patients carrying mutant EGFR. Platinum-based doublet therapy (for example, cisplatin in
combination with another cytotoxic therapy) has been the standard therapy for patients with
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advanced stage NSCLC and shows a superior performance status (Herbst et al., 2018).
Particularly, adjuvant cytotoxic therapy with a cisplatin-based doublet administrated to
patients in stages II and IIIA NSCLC yielded improved survival with complete resection.
Also, Hotta et al., 2004, analyzed eight clinical trials and reported a higher response rate
for cisplatin compared with carboplatin treatment with no survival difference. In the same
study, subgroup analyses revealed that patients treated with cisplatin alone had longer
survival than those receiving a third generation TKI in conjunction with carboplatin.
Moreover, from the FLEX and BMS099 studies, it was revealed that cetuximab (antiEGFR monoclonal antibody) used as monotherapy after prior administration of TKIs
yielded no response (Wang et al., 2013). However, cetuximab addition to platinum doublet
cisplatin/vinorelbine demonstrated a significant improvement in overall survival benefit of
1.2 months in NSCLC patients with EGFR-positive tumors (Wang et al., 2013). Overall,
the above reports have demonstrated that cytotoxic chemotherapy regimens or their
combinations administered to patients with EGFR-wild-type NSCLC produced a better
response. Nonetheless, it must be mentioned that the median overall survival for EGFRwild-type NSCLC patients after chemotherapy treatment remains less than 1 year and the
progression-free survival is 6 months at the most (Lin et al., 2016). This indicates that
newer therapies with improved outcomes are needed for this unique NSCLC patient’s
population.

1.4.1.2 Chemotherapy as a successful treatment for TNBC
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The standard of systemic treatment for TNBC follows the same general principle with other
types of breast cancer. Therefore, neoadjuvant or adjuvant chemotherapy remains a key
component of systemic treatment in early and advanced TNBC, which is determined
primarily by its clinical or pathologic stage (Park et al., 2018). In previous pivotal
neoadjuvant trials, patients with TNBC showed significantly higher response rates to
anthracycline and taxane-based chemotherapy than those of other subtypes, achieving
pathologic complete response (pCR) rates of approximately 40% (Cortazar et al., 2014).
Subsequent clinical trials of metastatic TNBC showed a modest efficacy of platinum-based
monotherapy, consistently suggesting a greater benefit in BRCA1/2 mutation carriers. In
early TNBC, patients with stage II–III treated with neoadjuvant cisplatin alone showed a
22% pCR rate in a small retrospective study, in which only 7% of patients carried germLine
BRCA mutations (Byrski et al., 2014). Further phase II studies exclusively for patients
with BRCA1 mutation demonstrated markedly higher pCR rates from 61-90% after
neoadjuvant cisplatin monotherapy, which validated the significance of BRCA gene in
predicting platinum sensitivity in TNBC (Silver et al., 2010). Despite, the effectiveness of
single-agent chemotherapy, some TNBC non-responders were identified and that called
for the use of combinatorial chemotherapy. Masuda et al., 2017 report that the CREATEX trial demonstrated a potential survival benefit of adding capecitabine to the standard
adjuvant chemotherapy regimen in early TNBC with a residual tumor burden after
neoadjuvant treatment. Also, a meta-analysis by Natori and colleagues, 2017, provided
some justification for combining capecitabine with either neoadjuvant or adjuvant standard
chemotherapy in patients with TNBC. In a different phase II clinical trial, BRCA1/2mutant TNBC patients achieved the highest pCR rate of about 56% after neoadjuvant
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combination chemotherapy with gemcitabine, carboplatin, and the PARP inhibitor iniparib
(Telli et al., 2015). Despite the effectiveness of these treatment modalities, patients who
do not respond to chemotherapy develop resistance, and a more aggressive recurrent
disease results which then becomes virtually incurable (Székely et al., 2017; Wahba and
El-Hadaad, 2015).

Over the past three decades, targeted agents have been developed as a replacement therapy
to treat cancer patients with the idea of achieving selectivity, specificity, efficacy and
safety, as well as preventing adverse side effects. Some of these agents have already been
approved by the Food and Drugs Administration (FDA) for treating different cancers.
Targeted agents against EGFR are the most abundant in clinical use (Imai and Takaoka,
2006). Examples include monoclonal antibodies - (cetuximab and panitumumab) and
tyrosine kinase inhibitors - (erlotinib and gefitinib).

1.4.2

EGFR targeted therapy for TNBC and NSCLC patients-success and
challenges

1.4.2.1 EGFR targeted therapy as a successful treatment for NSCLC

In NSCLC, EGFR has been exploited as a molecular target for two distinct kinds of
molecules, monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKI). mAbs,
which are thought to be efficacious in EGFR wild-type NSCLC patients and target the
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extracellular domain of EGFR. On the other hand, TKIs which are effective in NSCLC
patients with mutations in the EGFR kinase domain, target the intracellular domain of
EGFR (Figure 1.4) (Imai and Takaoka, 2006). Usually, EGFR wild-type NSCLC patients
with advanced disease receive chemotherapy as a first-line of treatment, while TKIs
(gefitinib, erlotinib, afatinib) or mAbs (cetuximab, panitumumab and necitumumab) serve
as second line (Zhang et al., 2014) of treatment. EGFR wild-type NSCLC patients have
responded better to a chemotherapy regimen compared to anti-EGFRs. Notably, the
TAILOR trial (Tarceva Italian Lung Optimization Trial), which compared the efficacy of
erlotinib in patients with wild-type EGFR to that of docetaxel as a second-line therapy,
showed that the progression-free survival (PFS) was significantly better with docetaxel
than with erlotinib: median PFS was 2.9 months with docetaxel versus 2.4 months with
erlotinib (Morales-Espinosa and Rosell, 2015). In a similar Chinese trial, which compared
pemetrexed to gefitinib in wild-type EGFR non-squamous NSCLC patients, it was
observed that progression-free survival was significantly better with pemetrexed than
gefitinib and there was a trend for an improvement in overall survival in favor of docetaxel
(Sculier et al., 2015). Other studies have also reported that the combination of
chemotherapy and anti-EGFRs administered to EGFR wild-type NSCLC patients leads to
a superior overall response. Particularly, the FLEX trial demonstrated improved overall
survival for chemotherapy plus cetuximab in patients who harbored overexpressed (wildtype) EGFR in their tumors (Pirker, 2012). Similarly, the Sculier et al., 2015 study reported
that the addition of cetuximab to chemotherapy significantly improved the overall survival
and progression-free survival compared with chemotherapy alone. However, anti-EGFR
administered alone to this patient population is deemed ineffective by these same reports.

21

Therefore, in terms of evidence-based medicine, these studies are strongly against the use
of TKIs in wild-type EGFR NSCLC. In EGFR mutant NSCLC, two common mutations
observed are the L858R mutation in exon 21 and the exon 19 deletions. Both are found
within the tyrosine kinase domain and are drug-sensitizing mutations. These mutations
activate the kinase action increasingly and sustain the activated receptor in a gain-offunction manner through ligand binding. Therefore, it has been observed that del 19 and
L585R are gain-of-function mutations because they cause activation of the EGFR signaling
pathway in the mutant EGFR-positive oncogenic cells, and some of these mutations also
lead to greater sensitivity to EGFR TKIs compared to cases with wild-type EGFR (Pirker,
2012). TKIs are mainly recommended as either first- or second-line therapies for advanced
stage NSCLC patients with EGFR-mutations. TKIs are suggested to covalently bond to the
ATP binding sites of the tyrosine kinases, causing permanent inhibition to this site, whilst
also inhibiting the HER2 receptor. Many reports suggest that anti-EGFRs are highly
recommended for treating EGFR-mutant NSCLC patients due to improve overall response
rate and the significant increase in progression-free survival when compared to
chemotherapy. In support of this, the IPASS clinical study reported that tumor response
rate in patients with EGFR activating mutations was about 71.2% in the gefitinib group
which was statistically significant compared to 47.3% in the chemotherapy arm. The
primary endpoint of progression-free survival (PFS) was significantly prolonged in the
gefitinib treatment group (9.8 vs 6.4 months) (Yi-Long et al., 2012). In a similar study,
researchers randomized 173 NSCLC patients with EGFR mutations to erlotinib and
chemotherapy; The median PFS was 9·7 months in erlotinib set which was significantly
longer than 5·2 months in chemotherapy set (Nan et al., 2017). Despite the huge success
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reported for anti-EGFR targeted therapies for NSCLC patients, the overall survival after
anti-EGFR therapy, especially after TKIs administration, is less than 15% (Lin et al.,
2016), probably due acquired resistance, and a more aggressive disease phenotype develop
after a patient’s remission to treatment (Lin et al., 2016).

1.4.2.2 EGFR targeted therapy as a clinical need for TNBC

In cancers like NSCLC and colorectal cancer, anti-EGFR agents, small molecule tyrosine
kinase inhibitors and monoclonal antibodies, have been developed and are currently being
used to treat these diseases. Cetuximab and panitumumab are two mAbs that are approved
for the treatment of EGFR-expressing metastatic colorectal cancer with KRAS wild-type
phenotype. Osimertinib, gefitinib, afatinib, and erlotinib are few selective EGFR-TKIs
used as therapy for patients with metastatic NSCLC who carry activating EGFR mutations
(Rosa et al., 2015; Bartholomew et al., 2017). In TNBC, there is no classification for
patients based on their EGFR status, thus patients are not represented as harboring wildtype EGFR or mutant EGFR phenotypes. As reported above, chemotherapy is the preferred
treatment for TNBC patients. Nonetheless, several clinical trials report the use of already
discovered anti-EGFR agents, either alone or in combination with chemotherapy, as a
treatment option for TNBC patients (Baselga et al., 2005; Dickler et al., 2009; Nakai et al.,
2016). The use of anti-EGFRs mostly yielded partial responses. Juggling through previous
reports, in a phase II clinical trial, gefitinib and erlotinib used as monotherapies in
metastatic and recurrent TNBC patients returned only a partial response of about 3%
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(Baselga et al., 2005; Dickler et al., 2009). In another phase II clinical trial with secondgeneration irreversible EGFR TKI, afatinib, no objective responses were produced in
patients with metastatic TNBC (Nakai et al., 2016). However, the combination of antiEGFR TKI and chemotherapy generated improved responses as suggested by some recent
studies. Noticeably, in a phase II clinical study, the combination of cetuximab plus
carboplatin or irinotecan or ixabepilone or docetaxel showed an improved response rate
compared to the single agents alone (Carey et al., 2012; Trédan et al., 2015; Crozier et al.,
2016; Nabholtz et al., 2016). In the same phase 2 trial, gefitinib, an EGFR TKI, was
reported to have minimal activity in patients' with advanced TNBC, and modest activity
when combined with standard chemotherapy in the patients population (Bernsdorf et al.,
2011). From all the above reports, it is evident that no anti-EGFR agents are currently
approved for TNBC treatment, as results from clinical trials are disappointing. This is often
attributed to the existence of compensatory pathways that confer resistance to EGFR
inhibition, thus allowing continued cancer cell growth and survival (Diluvio et al., 2018).
Therefore, the need for a more effective treatment modality is imminent and natural
products have proven to be the main source for the discovery of anticancer therapies.
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Figure 0.4 Anti-EGFR targets in NSCLC. Monoclonal antibodies target the extracellular
domain of EGFR. TKIs, small molecules, target the kinase domain of EGFR. Figure
adapted from Farhat and Houhou, 2013.
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1.5

Natural products as a rich source of discovering novel anticancer therapies

Natural products are often regarded as sources of phytochemicals or drug leads for the
discovery of novel drugs. Phytochemicals are naturally occurring secondary metabolites,
i.e. biologically active compounds found in plants, animals, microorganisms, and marine
organisms, that are able to inhibit various diseases including cancer. Notable examples
include the vinca alkaloids (vincristine and vinblastine) isolated from Catharanthus roseus,
as well as taxol isolated from Taxus brevifolia for the treatment of various cancers
(Acheampong et al, 2017; Larbie et al, 2015; Acheampong et al, 2015). In the face of
worldwide disease challenges, natural products research and development potentially play
a key function in innovative drug discovery. About 33% of FDA-approved drugs over the
past two decades are based on natural products or their derivatives and these have
transformed medicine (Thomford et al, 2018).

1.5.1

Cucurbitacins as important antitumor agents

Numerous successful anticancer drugs in clinical use are either natural products or their
synthetic analogs. For this reason, cucurbitacins (cucs) and their analogs have become a
focus of research because of their ability to significantly inhibit the growth of distinct
cancers. Cucs belong to a large family of triterpenoids present in Cucurbitaceae plants, and
possess many biological activities, with the most relevant a without doubt being anticancer
properties toward different cancers (Sikander et al., 2016; Hall et al., 2015). There are
about 18 members in this family. Notably, cucurbitacin B, its derivative and semisynthetic
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analogs are documented to induce apoptosis by suppressing Akt and MAPK signaling as
well as inhibiting metastasis and invasion in A549 lung cells (Silva et al., 2016). Moreover,
Wang et al., 2016 reported that cucurbitacin A inhibited the growth of A549 lung cells via
arresting the G2/M phase of the cell cycle and modulating Akt signaling. Furthermore, the
outcome of the studies by Shukla et al., 2016 revealed that Cuc B demonstrated strong antimigratory and anti-invasive capabilities against metastatic NSCLC at nanomolar
concentrations; This inhibition of metastasis and angiogenesis was attributed to the
downregulation of the Wnt/β-catenin signaling axis. In TNBC, findings by Kong et al.,
2014, showed that Cuc E significantly inhibited the growth of the MDA-MB-468 and
SW527 cell models by inducing cell cycle arrest within the G2/M phase, inducing
apoptosis, and inhibiting ERK and AKT expressions. Also, Sinha et al., 2016,
demonstrated that treatment with Cuc B significantly inhibited the migratory and invasive
potential of MDA-MB-231 and 4T1 cells; Cuc B significantly inhibited the vascular
endothelial growth factor (VEGF)-induced phosphorylation of focal adhesion kinase and
MMP-9 signaling. The important anticancer activity of the Cuc compounds is as a result
of unique pharmacophores present on each member. Despite the promising anticancer
activities of Cucs, some challenges have been identified that limits their usefulness. These
compounds are secreted in minute quantities in plants and isolating substantial amount
remains a challenge. Also, low doses of Cucs administered to mammals elicit adverse
toxicity effects. Moreover, the total synthesis of Cucs is challenging due to the complexity
of their structure. Interestingly, Cucs possess a similar base-scaffold to estrone with a minor
difference. To overcome the challenges identified, a simple solution would be to use
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estrone as a starting material and then introducing the anticancer pharmacophores of Cucs
to synthesize novel hybrid.

1.5.2

Estrone analogs as effective anticancer small molecules

Estrone, a major mammalian estrogen, is naturally converted from androstenedione or from
testosterone via estradiol and estrone sulfate. Estrone is in high demands nowadays as most
synthetic or medicinal chemists use it as a starting material to synthesize novel derivatives.
Some studies suggest that derivatives of estradiol, an isomer of estrone, exert significant
antimitotic effects against various cancers including breast cancer. In particular, Stander et
al., 2011 report that 2-methoxyestradiol (2ME), an endogenous metabolite of 17βestradiol, possess both antiangiogenic and anti-breast cancer effects in vitro and in vivo.
This compound exerts its cytotoxic effect independently of the cellular estrogen receptors
and has no significant systemic hormonal effects (Leese et al., 2006). Estradiol, however,
promotes the proliferation of various cancers (Verwey et al., 2016). The above studies also
report on the limited bioavailability of 2ME (Panzem®) due to its fast-metabolic
breakdown during phase II clinical studies. Recently, a sulfamate derivative of 2ME has
been found to possess potent antitumor activity against breast cancer cells due to its
increased bioavailability by avoiding hepatic first-pass metabolism (Visagie et al., 2013;
Verwey et al., 2016). A similar study reports the induction of mitochondrial apoptosis as
the underlying mechanism for the observed cytotoxicity of 2ME sulfamate derivative
against the NSCLC model, A549 (Nolte et al., 2018). This suggests that estrone maybe a
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privileged scaffold upon which modifications can be added to generate lead candidates
with improved potency, pharmacokinetic properties and reduced toxicities. Discovering
new drugs through research and development in the pharmaceutical industry is traditionally
a tedious process which involves high cost. Novel approaches are always needed to reduce
time and cost. Molecular docking is one means to provide a fast prediction of the proposed
compounds' behavior against a biological target with a low cost (Csermely et al, 2013).

1.5.3

Molecular docking studies as first steps toward drug discovery

Molecular docking is a process where small organic compounds or large macromolecules
like antibodies are fitted into the active site of target molecules, usually proteins to predict
the molecules desirable properties. The main goal of this process is to find the most stable
(lowest energy) conformer that interacts with the active site of the molecular target. Thus,
molecular modeling is a powerful technique that can predict the characteristics of a set of
compounds with specific pharmacophores based on their interaction with the targeted
protein. This has often led to the identification of promising hits and novel lead candidates.
The entire molecular docking process begins with building a library of compounds, then
generating the appropriate conformation of the receptor of interest and finally performing
the docking simulations to identify the hit compounds with better binding affinity and
potency. Afterward, the large compound library is narrowed down into predicted active
compounds, enabling optimization of lead compounds by improving the biological
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properties, like affinity and absorption, distribution, metabolism, excretion, and toxicity
(ADMET) (Osakwe and Rizvi, 2016).

It is noteworthy to mention that the drug discovery process has improved since
computational approaches emerged over three decades ago (Osakwe and Rizvi, 2016).
Several computational methods have been used in the drug discovery process. These
include but are not limited to computer-aided drug design (CADD) and fragment-based
drug discovery (FBDD). CADD entails a vast number of computational methodologies
including virtual screening. Virtual screening technique can be divided into ligand- and
structure-based drug design techniques (LBDD and SBDD).

LBDD usually takes

advantage of information from known bioactive compounds (ligand) and are essential tools
when structural information of a biological target is missing or when the molecular design
is not directed toward a target-centric approach but intended to modulate cellular pathways
or phenotypic traits without a precise knowledge of the mechanism of action (Del Rio and
Varchi, 2016). SBDD usually exploits the three-dimensional (3D) structure of the
biological target (protein) to identify putative modulators of the protein activity. The
compounds that show high binding affinity to the target protein, called "hits", are screened
in a high-throughput bioassay screening (HTS) to identify the lead compound (Wolber and
Sippl, 2015).

1.6

Research strategy and objectives
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In our research group, estrone analogs are designed in silico for superior pharmacokinetics
and virtually screened against different receptors including the EGFR kinase domain. The
virtual hit compounds are subsequently synthesized using estrone as a starting material
(Figure 1.5) and further tested for their cytotoxic effects before elucidating their
mechanism of action. Many of our estrone derivatives, especially those bearing
cucurbitacin pharmacophores have previously demonstrated potent cytotoxic effects
against distinct cancers in vitro (Kopel et al., 2013; Ahmed et al., 2017; Ahmed et al.,
2014). Recently, a new series of estrone analogs (bearing either a modified cucurbitacin
(MMA series) or triazole (Fz series) pharmacophores) have been synthesized and found to
be potent against EGFR’s kinase domain in silico and cytotoxic against EGFR dependent
cancers, viz models of NSCLC and TNBC in vitro compared to the TKIs, erlotinib and
sorafenib. This raises the question, “could these novel estrone analogs be more effective in
the treatment of EGFR-dependent cancers than the current EGFR TKIs? We, therefore,
hypothesized that the lead candidates will have a superior set of qualities for preclinical
and clinical development compared to the current EGFR TKIs.
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Figure 0.5 Design strategy for hybrid estrone derivatives. Estrone is used as a scaffold
upon which modifications are made to obtain MMA or Fz series of compounds.
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Objective 1: Screen a library of estrone analogs against EGF receptor in silico using a
computer-aided molecular modeling (CAMM) to identify potential virtual hits.
To address the goal of our study, we first performed molecular docking studies to identify
hits from our drug libraries. The co-crystallized structure of the EGFR kinase domain (PDB
code: 2ITW, 1M17) was prepared and the three-dimensional structures of the estrone
analogs constructed using Chem. 3D ultra 12.0 software. Virtual screening was carried out
using the FRED application (version 2.2.5) of OpenEye® software. A lower consensus
score indicated better potency and binding affinity of the ligands toward the receptor. For
objective 1, the following research questions were investigated: I. Do the estrone analogs
show better potency and binding compared to the co-crystallized compounds? II. What are
the key molecular interactions utilized by estrone analogs to achieve drug potency?

Objective 2: Investigate the cytotoxic effects of estrone analogs against cancer cell lines
using cell viability assays in vitro.
During the research and development process, to predict the therapeutic use of a new
compound, one must know its biological activity and corresponding toxicity. Cell-based
assays in the form of monolayer cell culture screens are usually the first approach used to
confirm a compounds biological activity and cytotoxicity. In this objective, cell viability
assays, including MTT and trypan blue cell counting, were employed to establish the
cytotoxicity of the compounds. This allowed us to answer the question, are our hit
compounds were more potent against NSCLC and TNBC cell lines compared to known
TKIs in vitro?
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Objective 3: Elucidate the estrone analogs molecular mechanism of action in cancer
cells using cell-based and immuno assays in vitro.
When elucidating the mechanism of action of antitumor drugs, the extent of the
compound’s ability to inhibit cell proliferation, induce the death of a cell, or both are
considered. There are diverse ways of determining inhibition of cell proliferation, but
usually, inhibition of cell cycle progression depicted by an accumulation of DNA within
distinct phases of the cell cycle is widely exploited by scientists. Also, programmed cell
death (apoptosis) investigation is the most popular cell death mechanism studied by many
researchers. In the third objective, both cell-based assays and immuno-assays were adopted
to characterize the compound’s mechanism of action that underlies their observed
cytotoxicity. For this objective, we asked, “do estrone analogs inhibit NSCLC and TNBC
cells proliferation or induce apoptotic cell death or both?”

1.7

Research relevance and innovation

Chemotherapy and anti-EGFRs are the current treatment modalities recommended for
TNBC and NSCLC patients, respectively. Chemotherapy is effective and non-selective in
its action whereas anti-EGFRs either irreversibly bind to the ATP binding site of EGFR
kinase domain or EGFR extracellular domain in their mode of action. Despite the
significant success of these therapeutic interventions over the years, acquired resistance
and aggressive recurrent disease have been reported. Therefore, the search for potent and
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safe next generation anti-EGFRs is imperative. Estrone analogs have shown great promise
in various preclinical and clinical studies. These compounds exert their cytotoxic effect
either dependently or independently of the cellular estrogen receptors. Particularly, Visagie
et al., 2013; Verwey et al., 2016 report on a sulfamate derivative of 2ME that has been
found to possess potent antitumor activity against breast cancer cells due to its increased
bioavailability by avoiding hepatic first-pass metabolism. Also, a similar study reports
induction of mitochondrial apoptosis as the underlying mechanism for the observed
cytotoxicity of 2ME sulfamate derivative against the NSCLC model, A549 (Nolte et al.,
2018). The above studies made modifications to the C-2 (ethyl group), C-3 (sulfamoyl or
methoxy moieties) and C-17 (ketone or hydroxy functionalities) positions of the estrone
skeleton. Amr et al., 2019 reports on the synthesis of estrone derivatives using estrone aryl
methylenes as a starting material. This study reports that the most effective compounds
showed better binding towards EGFR, VEGFR-2 and induced p53 ubiquitination in MCF7 cells. Amr and colleagues, 2019 in their design strategy made modifications (attached a
heterocyclic ring) to C-16 and C-17 of the estrone scaffold.
It is interesting to note that during the pathogenesis of lung cancer, a type of non-hormonal
cancer, estrogen receptor and aromatase enzyme which are important for estradiol
biosynthesis and modulation are overexpressed. These proteins together with EGFR helps
lung cancer cells to use estradiol for their growth and survival through the non-genomic
pathway. Even though hormone receptors under expression have been observed in TNBC,
EGFR overexpression persists especially in the advanced stage of the disease. Therefore,
targeting EGFR, a central regulator of cell proliferation, is a promising strategy to
inhibiting various downstream signaling pathways and ultimately inhibiting the growth of
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cancer. We have designed a different series of estrone analogs against EGFR by installing
unique potent pharmacophores onto the estrone base scaffold yielding the MMA and Fz
series of compounds. The positions on the estrone skeleton targeted by our research group
are C-3 (various functionalities including methoxy, sulfamoyl, hydroxy, phenyl, etc.) and
C-17 (cucurbitacin pharmacophores or their modifications, triazole pharmacophore or its
modifications, etc.). The pharmacophores we introduced onto the estrone scaffold make
our design and synthesis approach very novel. We suggest that our new analogs may hold
the key to treating serious EGFR-specific cancers like NSCLC and TNBC. The current
research is novel and innovative because for the first time these estrone analogs have been
synthesized and their cytotoxic effects evaluated against EGFR-dependent cancers, viz.
NSCLC and TNBC monolayer models.
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Chapter 2

Novel estrone analogs inhibit NCIH226 cells proliferation by suppressing EGFR
and ERK1/2 pathway as well as arresting G1 phase of the cell cycle.
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2.1

Abstract

Lung cancer is the deadliest human cancer globally, with non-small cell lung cancer
(NSCLC) being the most frequent type. Epidermal growth factor receptor (EGFR), a
central regulator of tumor progression is frequently overexpressed in NSCLC and is a key
drug target. Here, we describe the in-silico design and synthesis of novel estrone analogs:
a hybrid of modified cucurbitacin (Cucs) pharmacophore and estrone base-scaffold as
potent inhibitors of NCIH226 cells. Molecular docking studies revealed that most estrone
analogs exhibited better potency and binding than the positive controls, erlotinib and
sorafenib, when fitted into wild-type EGFR ATP binding site (pdb code: 2ITW). Moreover,
two of the analogs, MMA307 and MM320, significantly inhibited the proliferation of
NCIH226 cells with IC50 dose of 2.88 ± 0.21 and 9.68 ± 0.24 µM respectively, compared
to the positive control, sorafenib, IC50 molarity of 20.62 ± 1.32 µM. Exposing NCIH226
cells to IC50 concentration of MMA307 and MMA320 resulted in downregulation of EGFR
and phospho-EGFR expression levels, and suppression of activated MAPK-ERK1/2
signaling proteins; phospho-B-Raf, phospho-MEK1/2 and phospho-ERK1/2. Furthermore,
downregulation of cyclin D1 and concomitant upregulation of phospho-cyclin D1 and
p21waf1/cip1 were observed after the compounds’ addition to NCIH226 cells resulted in G1
phase cell cycle arrest. MMA320 but not MMA307 downregulated the expression levels
of Dyrk1B, a checkpoint kinase at the G1-S phase transition of the cell cycle. To conclude,
the present study is the first to report on the antiproliferative potential of novel estrone
analogs and provide evidence that MMA307 and MMA320 are promising novel lead
candidates for the development of anti-lung cancer drugs.
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2.2

Introduction

Lung cancer has the highest mortality rate worldwide and accounts for more than a
quarter of all cancer-related deaths (Siegel et al., 2018). Among patients with lung cancer,
25-40% have brain metastases at some point during their disease (Siegel et al., 2018). Nonsmall cell lung cancer (NSCLC) (~85%) is the most frequent type; “non–small cell” refers
to the type of cell within the lung where the cancer originated. In the last few years, the
discovery of EGFR as a key driver of NSCLC has led to the classification of patients as
either harboring mutations in EGFR kinase domain-mutant EGFR or overexpressed EGFREGFR wild-type NSCLC. An estimated 45-70 % of NSCLC cases have EGFR frequently
overexpressed (Forcella et al., 2017).

EGFR amplification is an important oncogenic strategy that drives cancer cell
proliferation. EGFR is a member of the human epidermal growth factor receptor (HER)
family of receptor tyrosine kinases that consists of four members: HER1, HER2, HER3
and HER4. Activation of EGFR through ligand binding promotes receptor dimerization
and autophosphorylation which initiates various signaling cascades, one of which is the
RAS/RAF/MEK/ERK network. The ERK-MAPK pathway is initiated through the
promotion of Ras binding to guanosine triphosphate (GTP), which in turn activates RAF
kinases MAPK/extracellular signal-regulated kinases (MEK), and ERK (MacCorkle and
Tan, 2005). Activated ERK is thought to translocate into the nucleus, where it
phosphorylates and activates numerous targets, elk-1, c-jun, fos, etc. (MacCorkle and Tan,
2005). These transcription factors control the expression of downstream cell cycle
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regulators, including cyclin D and p21waf1/cip1 as well as Dyrk1B (dual-specificity tyrosine
phosphorylation-regulated kinase 1B), a checkpoint kinase important for G1 to S phase cell
cycle transition (MacCorkle and Tan, 2005). Cyclin D overexpression and p21waf1/cip1
downregulation are often associated with cancer development. Cyclin D1, a D-type cyclin
and well-characterized oncogenic protein, forms active complexes with cyclin-dependent
kinases (CDK) 4/6, which phosphorylate and inactivate retinoblastoma tumor suppressor
(Rb), leading to the activation of the transcription factor E2F and upregulation of target
genes essential for progression from G1 to S phase of the cell-cycle (Torii et al., 2006). On
the other hand, p21waf1/cip1 causes G1 phase cell cycle arrest through phosphorylation of
cyclin D1 that leads to its ubiquitination and degradation. Dyrk1B, a G1-S phase checkpoint
kinase, is amplified or overexpressed in certain cancers including NSCLC signifying that
it may be an oncogene (Gao et al., 2013; Ashford et al.,2014). Dyrk1B is thought to arrest
damage tumors in the G0/G1 phase to allow their repair in the quiescent state and maintain
the clonogenicity of tumors via mediating cyclin D1 turnover and stabilizing p21 waf1/cip1
(Gao et al., 2013; Ashford et al.,2014).

In the past three decades, EGFR has been exploited as a molecular target for two
distinct kinds of molecules, monoclonal antibodies (mAbs) and tyrosine kinase inhibitors
(TKI). mAbs were thought to be efficacious in EGFR wild-type NSCLC patients while
TKIs are effective in NSCLC patients with mutations in the EGFR kinase domain (Imai
and Takaoka, 2006). Usually, EGFR wild-type patients with advanced disease are treated
with chemotherapy as first-line, and TKIs (gefitinib, erlotinib, afatinib) or mAbs
(cetuximab, trastuzumab) as second-line treatment (Nun et al., 2017; Zhang et al., 2014).
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It is noteworthy to mention that some clinical trials report that TKIs and mAbs are effective
first line agents like chemotherapy in treating EGFR wild-type NSCLCs. Notably, studies
by Gridelli et al., 2012; Shepherd et al., 2005 conveyed TKIs or mAbs as beneficial agents
against unselected NSCLC patients in terms of response rate and overall survival.
Moreover, Zhao et al., 2017 and Scholl et al., 2010 documented that EGFR wild-type
NSCLC patients with advanced disease are sensitive to TKIs or mAbs or a combination of
TKIs and mAbs. However, recent studies report that most patients eventually experience
recurrent disease within 12 to 14 months after anti-EGFR treatment and patients five-year
survival after anti-EGFRs exposure is approximately 15% (Wu and Shih, 2018; Ali et
al.,2013). Additionally, the long-term administration of anti-EGFR therapy accompanies
with acquired resistance which limits the treatment efficacy, leading to aggressive tumors
and rapid metastasis (Inoue et al.,2016; Qi et al., 2018). Thus, in addition to exploring the
in-depth drug resistance mechanism of existing drugs, as well as the relationship between
EGFR-mediated signaling pathways and tumor specificity, discovering a novel type of
targeted agents with improved efficacy and lower toxicity as an alternative therapy to treat
these unique patient population is a promising strategy.

Numerous successful anticancer drugs in clinical use are either natural products or
their synthetic analogs. In this perspective, cucurbitacins (cucs) and their analogs have
become a focus of research because of their capability to significantly inhibit the growth
of distinct cancers. Cucs belong to a large family of triterpenoids present in Cucurbitaceae
plants, and possess many biological activities, with the most relevant without a doubt is
anticancer properties toward different cancers (Sikander et al., 2016; Hall et al., 2015;
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Chung et al., 2015; Zhang et al., 2014). Notably, cucurbitacin B, its derivative and
semisynthetic analogs are documented to induce apoptosis through suppressing Akt and
MAPK signaling as well as inhibiting metastasis and invasion in A549 lung cells (Silva et
al., 2016). Moreover, Wang and colleagues, 2017 report that cucurbitacin A inhibited the
growth of A549 lung cells via arresting the G2/M phase of cell cycle and modulating Akt
signaling. Cucs are secreted in minute quantities in plants and isolating substantial amount
remains a challenge. Also, the total synthesis of Cucs is difficult due to the complexity of
Cucs structure. Interestingly, there is as structure similarity between Cucs and estrone with
a minor difference. Estrone, a major mammalian estrogen, is naturally converted from
androstenedione or from testosterone via estradiol and estrone sulfate. Previous studies
report that estradiol derivatives possess antimitotic activity. Particularly, a sulphamoylated
analog of 2-methoxyoestradiol has been found to be effective against NSCLC due to its
increased bioavailability (resist first pass of liver metabolism) (Stander et al., 2013; Stander
et al., 2012; Stander et al., 2011). These and similar studies suggest that estrone may be a
privileged skeleton upon which pharmacophores can be introduced to generate hybrid
analogs with superior pharmacokinetics and improved toxicity. In our research group,
estrone analog- a hybrid of modified cucs pharmacophores and estrone base-scaffold are
in silico designed against important clinical targets including EGFR. In the present study,
we report on the design and synthesis of novel estrone analogs, and the compounds
inhibition of NCIH226 cells proliferation. We found that two novel analogs labeled as
MMA320 and MMA307 inhibited the proliferation of NCIH226 cells. Modulation of
EGFR and multiple MAPK-ERK1/2 pathway proteins, as well as deregulation of G0/G1
phase cell cycle regulators, were observed in response to the compound’s treatment. The

59

results presented herein suggest that lung tumors can be successfully targeted with the
novel estrone analogs, MMA320 and MMA307.

2.3

2.3.1

Experimental section

Reagents and chemicals

Antibodies against EGF Receptor (D38B1) XP®, Phospho-EGF Receptor (Tyr1173)
(53A5), B-Raf (55C6), Phospho-B-Raf (Ser445), p44/42 MAPK (Erk1/2) (137F5),
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (197G2), MEK1/2 (L38C12),
Phospho-MEK1/2 (Ser217/221) (41G9), β-Actin (8H10D10), p21Waf1/Cip1 (12D1), Cyclin
D1 (92G2) and anti-rabbit DyLight 680 conjugate (5366) secondary antibody were
purchased from Cell Signaling Technology (Danvers, MA, USA); phospho-cyclin D1
(Thr286) (A537487) and anti-mouse DyLight 800 conjugate (W10815) from Thermo
Fisher Scientific (Waltham, MA, USA); p-EGFR Antibody (Y1068) (15A2), Dyrk1B
(A2309) and GAPDH (D1613) were from Santa Cruz Biotechnology Inc. (Dallas, Texas,
USA). The bicinchoninic acid (BCA) protein assay reagent kit, Vybrant® DyeCycle™
Green Stain, phosphate buffered saline (PBS) and trypan blue solution were from Thermo
Fisher Scientific (Waltham, MA, USA). Compound cytotoxicity was evaluated through
measurement of mitochondrial dehydrogenase activities with 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) reagent (Sigma-Aldrich, St. Louis, MO, USA).
Sorafenib (positive control) (Selleckchem, Houston, TX, USA) and novel synthetic
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cucurbitacin inspired estrone analogs were dissolved in dimethyl sulfoxide (DMSO)
(Fisher Chemical/Fisher Scientific). All other chemicals were of analytical grade.

2.3.2

Design and synthesis of estrone analogs

2.3.2.1 Molecular modeling

Molecular docking of novel estrone analogs into the three-dimensional X-ray structure of
wild-type EGFR ATP binding site (PDB code: 2ITW) was carried out using the FRED
application (version 2.2.5) as implemented through the graphical user interface of
OpenEye® software. The 3D structure of the above protein was downloaded from Protein
Data Bank. The three-dimensional structures of the hybrid analogs were constructed using
Chem. 3D ultra 12.0 software [Chemical Structure Drawing Standard; Cambridge Soft
Corporation, USA (2010)]; compounds were energetically minimized using MMFF94
application with 5000 iterations and minimum RMS gradient of 0.10. All bound water
molecules and ligands were eliminated from the proteins. Furthermore, multi-conformers
were generated using OMEGA application (version 2.5.1.4) and VIDA application
(version 4.1.2) was used as a visualization tool to show the potential binding affinity and
binding interactions of the ligands to the receptor (Elshaier et al., 2017). This software
package generates consensus scoring which is a filtering process to obtain virtual binding
affinity. The lower the consensus score, the better potency and binding affinity of the
ligands towards the receptor.
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2.3.2.2 Synthesis of MMA307 and MMA320

2.3.2.2.1 General procedure for the preparation of MMA307

Steps 1 to 9 has been previously reported by our research group (Mahnashi, 2017; Kopel
et al.,2013). Preparation of 10 was carried out as follows: 0.15 g of 9 was dissolved in N,
N-dimethylacetamide (0.8 mL) and incubated with sulfamoyl chloride (0.12 g, 0.945
mmol) at 0ºC. Subsequently, the reaction mixture was stirred at room temperature for 18
hrs and the resulting solution extracted with 1:1 mixture of ethyl acetate and water. The
residue was purified using silica gel column chromatography (ethyl acetate: n-hexane, 3:7)
to isolate compound 10 which was labeled as MMA307 (0.16 g, 91%). MMA307 was
characterized by 1H and

13

C NMR and high-resolution mass spectroscopies (Mahnashi,

2017).
MMA307 1H NMR (600 MHz, Chloroform-d) δ 8.21 – 8.18 (m, 2H), 7.77 (d, J = 15.7 Hz,
1H), 7.71 – 7.67 (m, 2H), 7.25 – 7.21 (m, 1H), 7.10 (d, J = 15.7 Hz, 1H), 7.01 (dd, J = 8.6,
2.6 Hz, 1H), 6.95 (d, J = 2.6 Hz, 1H), 5.03 (s, 2H), 3.98 – 3.89 (m, 1H), 3.83 (s, 1H), 2.78
(qd, J = 10.4, 9.7, 4.3 Hz, 2H), 2.29 – 2.21 (m, 2H), 2.16 (dq, J = 12.0, 4.2 Hz, 1H), 1.84
– 1.77 (m, 2H), 1.64 – 1.56 (m, 2H), 1.56 – 1.53 (m, 2H), 1.50 (s, 3H), 1.41 – 1.31 (m, 2H),
0.88 (s, 3H).
MMA307

13C

NMR (151 MHz, CDCl3) δ 203.04 (C21), 148.81 (C3), 147.90 (C27),

142.60 (C23), 140.35 (C24), 139.64 (C5), 138.92 (C10), 129.26 (C25, C29), 126.73 (C1),
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124.25 (C26,C28), 122.29 (C22), 121.93 (C4), 118.95 (C2), 79.54 (C19), 55.66 (C14),
54.98 (C17), 44.31 (C8), 43.97 (C13), 40.51 (C12), 37.65 (C15), 29.51 (C6), 27.26 (C11),
26.43 (C7), 24.22 (C9), 23.64 (C20), 22.09 (C16), 13.65 (C18).
HR-FT-MS calcd for C29H34O7N2SNa 577.1979 found 577.19790.

2.3.2.2.2 General procedure for the preparation of MMA320

Steps 1 to 9 has been previously reported by our research group (Mahnashi, 2017; Kopel
et al.,2013). Synthesis of 10 was carried out as follows: to a stirred solution of the 9 (0.3
g, 0.847 mmol), a mixture of tetrahydrofuran and lithium diisopropylamine (LDA) (1.5
mL, 3.05 mmol) were added and the reaction kept at -78 ºC. After that, the reaction mixture
was initially stirred for 1 hr, before para-trifluoromethyl benzaldehyde (0.206 mL, 1.7
mmol) dissolved in THF added and the resulting mixture warmed to room temperature for
24 hrs. Subsequently, the reaction was quenched with ammonium chloride and the aqueous
layer extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtrated, and
concentrated under vacuo. Silica gel column chromatography was used to purify the crude
material (ethyl acetate: n-hexane, 1:9) to obtain 10 (0.21 g, 61.7%). Pure compound 10 was
characterized by NMR and mass spectroscopies and labelled as MMA320 (Mahnashi,
2017).
MMA320

1H

NMR (600 MHz, Chloroform-d) δ 7.77 (d, J = 15.8 Hz, 1H), 7.61 – 7.57

(m, 4H), 7.04 – 6.99 (m, 2H), 6.59 (dd, J = 8.6, 2.7 Hz, 1H), 6.53 (d, J = 2.7 Hz, 1H), 6.02
– 5.88 (m, 1H), 4.32 (s, 1H), 3.67 (d, J = 2.3 Hz, 3H), 2.78 (dtd, J = 34.0, 17.3, 6.5 Hz,
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2H), 2.21 (ddd, J = 15.4, 6.3, 3.4 Hz, 1H), 2.11 (dt, J = 12.8, 3.7 Hz, 1H), 2.03 – 2.00 (m,
1H), 1.81 (dt, J = 12.2, 3.3 Hz, 2H), 1.52 (dd, J = 10.8, 2.4 Hz, 1H), 1.47 – 1.43 (m, 2H),
1.30 (dt, J = 12.2, 6.2 Hz, 1H), 1.11 (td, J = 12.7, 4.4 Hz, 2H), 0.97 (s, 3H).
MMA320

13C

NMR (151 MHz, CDCl3) δ 200.68 (C21), 157.44 (C3), 155.17 (C17),

142.95 (C23), 137.84 (C24), , 132.75 (C5), 132.41 (C10), 132.20 (C27), 129.74 (C1),
128.81 (C25, C29), 126.02 (C22) , 124.66 (C26,C28), 122.86 (C30), 121.09 (C16), 113.83
(C4), 111.37 (C2) , 78.81 (C19) , 57.48 (C31) , 55.18 (C14), 47.86 (C9), 43.93 (C8), 37.09
(C13), 34.49 (C12), 31.23 (C15), 29.69 (C6), 27.59 (C11), 26.27 (C7), 25.26 (C9), 17.21
(C20), 14.16 (C18).
HR-FT-MS calcd for C31H33O3F3Na 533.2274 found 533.22544.

2.3.3

Cell culture

NCIH226 cell line (a model of EGFR wild-type and p53 mutant NSCLC) was a kind gift
from Prof. Xiangming Guan (College of Pharmacy and Allied Health Professions, South
Dakota State University, USA). The cells were cultured in Rose Park Memorial Institute
(RPMI)-1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS), 100 IU/mL
penicillin and 100 μg/mL streptomycin (American Type Culture Collection (ATCC)) at
37˚C equilibrated with 5% (v/v) CO2 in humidified air. The cells for the assays were
detached using a solution of trypsin with EDTA (ThermoFisher Scientific).
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2.3.4

Cell proliferation assays

2.3.4.1 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Assay

The effect of 25 novel synthetic estrone analogs on cell viability was tested with MTT
reagent as described by Wang et al., 2010 with slight modifications. Briefly, to measure
mitochondrial dehydrogenase activities, cells were seeded in 96-well plates at an initial
density of 30,000 cells per well. After overnight incubation, cells were treated with
different concentrations of compounds in a dose range of 0 - 100 μM. The final DMSO
concentration was 0.05%. After 48 hrs of incubation, 20 μL of MTT reagent (5 mg/mL)
was added to each well and the formed formazan crystals were dissolved in 250 μL of
dimethyl sulfoxide (DMSO). Four independent experiments were completed to determine
the mean optical density referred to as cell viability, using a Hidex Sense Beta Plus plate
reader (Turku, Finland). Cell viability was expressed as a percentage of DMSO-treated
controls.

2.3.4.2 Trypan Blue Exclusion Assay

Cells were seeded in six-well plates at a density of 300,000 cells/well in 3 mL RPMI media
and were treated with MMA320, MMA307 and Sorafenib at IC50 concentrations for 24 hrs
after overnight incubation. Afterward, cells were then detached using trypsin/EDTA and
counted with Countess II Automated Cell Counter (ThermoFisher Scientific, USA). At
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least two independent experiments were performed to determine the mean value, which is
presented as a percentage compared to the DMSO-treated controls.

2.3.5

Flow cytometry for cell cycle analysis

Cells were seeded into six-well plates at a concentration of 300,000 cells/well and allowed
to attach in culture overnight, then treated with IC50 values of compounds or positive
control (sorafenib) for 48 h. Afterward, cells were washed with PBS and harvested. Cell
cycle analysis was investigated by adding Vybrant® DyeCycle™ Green Stain (Thermo
Fisher Scientific) to 1 mL of cell suspension at a final concentration of 0.0625 μM. After
45 minutes incubation at 37˚C, the samples were analyzed by flow cytometry and
compared to DMSO-treated cells. All these experiments were performed on BD Accuri™
C6 flow cytometer (BD Biosciences, San Jose, CA, USA) using BD Accuri™ C6 software,
version 1.0.

2.3.6

Protein expression analysis

2.3.6.1 Western Blot

Western blotting was done as previously described by Shin et al., 2008 with slight
modification. Briefly, 80% confluent cells were washed three times with PBS prior to
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treatment with IC50 values of compounds for indicated times. Subsequently, cells were
lysed using lysis buffer containing 1% Triton X-100 and 1% Halt™ Protease Inhibitor
Cocktail (Thermo Fisher Scientific). Aliquots of lysates containing 20-60 μg of proteins
were boiled for 7 min in SDS-PAGE sample buffer supplemented with 5% βmercaptoethanol, separated on 10% polyacrylamide electrophoresis gels and transferred to
nitrocellulose membranes (Bio-Rad Laboratories). After transfer, membranes were
incubated with relevant antibodies against EGF Receptor, Phospho-EGF Receptor, B-Raf,
Phospho-B-Raf, MEK1/2, Phospho-MEK1/2, ERK1/2, Phospho-ERK1/2, p21Waf1/Cip1,
Cyclin D1, Phospho-Cyclin D1, Dyrk1B, and either β-actin or GAPDH, loading control,
followed by incubation with anti-mouse or anti-rabbit DyLight conjugated (680 or 800 nm)
secondary antibodies. Membranes were scanned with LICOR Odyssey® Fc Imaging
System (Lincoln, Nebraska, United States) and blots analyzed by Fiji software (Image J,
Java 1.8.0).

2.3.6.2 In-Cell Western (ICW) Assay

ICW was carried out in accordance with manufacturers instruction with slight
modifications. Briefly, about 40,000 cells per well were seeded in 96-well black walled
plate with clear bottom for overnight attachment. Cells were then washed three times with
PBS prior to treatment with MMA307 (IC50 value) for indicated times. Subsequently, cells
were fixed with 3.7% formaldehyde solution, permeabilized with 0.1% Triton X-100
solution and blocked with fish gel buffer (1×) prior to primary antibody addition. Wells
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were then incubated with the relevant antibodies EGF Receptor, Phospho-EGF Receptor,
MEK1/2, Phospho-MEK1/2, ERK1/2, Phospho-ERK1/2, Dyrk1B, and GAPDH, loading
control, overnight followed by incubation with anti-mouse or anti-rabbit DyLight
conjugated (680 or 800 nm) secondary antibodies. Images were acquired using LICOR
Odyssey® Fc Imaging System (Lincoln, Nebraska, United States) and image quantification
done by Fiji software (Image J, Java 1.8.0).

2.3.7

Statistical Analysis

Microsoft® Excel® for Windows, version 16.0., was used for the calculation of mean and
standard deviation values of different experiments and plotting of bar or line graphs. Mean
IC50 values were compared by one-way Analysis of Variance (ANOVA) using GraphPad
Prism 5.01 (San Diego, USA) and values with p<0.05 were considered statistically
significant.

2.4

Results and Discussion

Installing various modified cucurbitacin functionalities and other pharmacophores
onto the estrone scaffold resulted in unique hybrid analogs. To validate the potential of
these designed estrone analogs against wild-type NSCLC, molecular docking was
performed by fitting the designed hybrid analogs and reference compounds (erlotinib and
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sorafenib) into the ATP binding site of EGFR (PDB codes: 2ITW) crystallized from wildtype NSCLC. The results were plotted as a line-scatter graph (Figure 2.1), which mainly
displays the corresponding consensus scores of the molecular docking studies. Compared
to erlotinib and sorafenib, it was clearly observed that most estrone analogs showed lower
consensus scores (a measure of better binding and potency) against the wild-type EGFR
ATP binding site. Furthermore, Figure 2.2 and 2.3 showed EGFR with the binding mode
of compounds MMA307, containing sulfamoyl and paranitrophenyl groups, and
MMA320, with para-trifluoromethylphenyl and methoxy substituents that exhibited potent
antiproliferative activity in vitro compared to sorafenib. Previous studies by Yun et al.,
2007 suggested that hydrogen bonding towards the amino acid residue, MET793A, in the
EGFR kinase domain may be a key interaction in achieving effective drug potency. We
observed that the positive controls, erlotinib (Tarceva) showed hydrogen bonding from the
pyrimidine-N2 towards MET793A and sorafenib (Nexavar) showed hydrogen bonding
from pyridine-N, methyl-H and carbonyl-O towards THR854A and THR790A,
respectively but registered a higher consensus score (Figure 2.4 and 2.5). Analyzing
compound MMA320 in the EGFR-binding site revealed hydrogen bonding from the
methoxy carbonyl-O on the substituent group towards the amino acid residue THR854A
(Figure 2.3). However, examining MMA307 enriched with functionalities capable of
hydrogen bonding within the EGFR kinase domain demonstrated hydrophobichydrophobic (cation-π) interactions towards the amino acid residue, LYS745A (Figure
2.2). Both MMA320 and MMA307 recorded lower consensus scores compared to the
positive controls. The hydrogen bonding exhibited by MMA320 toward THR854A and the
cation-π interactions exhibited by MMA307 toward LYS745A demonstrate a strong and
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unique binding mode and suggest that interactions between the compounds pharmacophore
and THR854A and LYS745A residues in the EGFR ATP binding site may be key in estrone
analogs achieving drug potency. These results could provide a molecular-level foundation
to illustrate that MMA307 and MMA320 can bind well at the active site of activated EGFR.
These findings are supported by their lower IC50 concentration compared to sorafenib from
the in vitro antiproliferative assays. Directed sulfamoylation on compound 9 afforded 10
(MMA307) in 91% yield after column chromatography (scheme 2.1) and the addition of
para-trifluoromethyl benzaldehyde to the hydroxyl methyl ketone diastereomeric mixture
yielded 61.7% of MMA320 after purification with silica gel column chromatography
(Scheme 2.2). These pure compounds were characterized by NMR and mass spectrometry
techniques with the 1H and 13C chemical shifts as well as accurate masses documented in
the

method

section.

MMA307

was

named

as

(8S,9S,13S,14S,17S)-

7,8,9,11,12,13,14,15,16,17-decahydro-17-((R,E)-2-hydroxy-5-(4-nitrophenyl)-3-oxopent4-en-2-yl)-13-methyl-6H-cyclopenta[a]phenanthren-3-yl sulfamate and MMA320 named
as

(R,1E)-1-(4-(trifluoromethyl)phenyl)-4-((8S,9S,13S,14S)-7,8,9,11,12,13,14,15-

octahydro-3-methoxy-13-methyl-6H-cyclopenta[a]phenanthren-17-yl)-4-hydroxypent-1en-3-one (Figure 2.6).

Subsequently, estrone analogs effect on the proliferation of NCIH226 cells were
determined by the MTT assay after 48 hrs. Overall, the compounds showed a significant
growth inhibitory effect toward the NCIH226 cells. Particularly, MMA287, MMA306,
MMA307, MMA320 and MMA321 showed significant (p < 0.001 to p < 0.05)
antiproliferative activity against NCIH226 cells at IC50 doses of 11.82 ± 0.65, 17.41 ± 1.56,
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2.88 ± 0.21, 9.68 ± 0.24 and 14.57 ± 0.31 μM, respectively (Table 2.1). MMA307 and
MMA320 were at least two to seven-fold more potent than the standard anticancer drug
sorafenib and were chosen for further studies. Morphological changes were evaluated after
NCIH226 cells were treated with IC50 concentrations of MMA307, MMA320, and
sorafenib (positive control). Compared with DMSO-control cells, the majority of the
compound-treated NCIH226 cells changed from spindle to either round- (observed for
MMA307 and sorafenib) or rod-shaped (observed for MMA320) (Figure 2.7 A) showing
the compounds growth modulatory effects. Furthermore, the growth inhibitory effects of
MMA307 and MMA320 at their IC50 doses were confirmed by the trypan blue exclusion
assay; shows increased cell membrane permeability for trypan blue dye by dead cells.
NCIH226 cells were treated for 24 hrs and no significant cell death as measured by trypan
blue stained cells were observed for MMA307 (Figure 2.7 B). A slight but statistically
insignificant increase in NCIH226 cell death was observed for both MMA320 and
sorafenib. It is well known that several cucurbitacin classes and their derivatives, estrone
analogs as well as anti-EGFRs with anticancer properties exhibit their cytotoxic effects on
tumor cells by inhibiting cell proliferation or inducing cell death (Wang et al., 2017;
Ahmed et al., 2017; Ahmed et al., 2014; Kutkowska et al., 2017). Comparing data obtained
through cell viability (MTT, trypan blue and morphological changes) and Vybrant® Dye
Cycle™ Green staining, we were able to distinguish between the two possible effects of
the estrone analogs: inhibition of cell proliferation and induction of cell death. Our findings
showed that, even though treatment with MMA320 leads to some amount of cell death, the
predominant effect of estrone analogs administration to NCIH226 cells is the inhibition of
cell proliferation. These results are supported by initial apoptosis (annexin v staining of
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phosphatidyl serine) detection using propidium iodide staining where no significant cell
death (data not shown) induced by MMA307 and MMA320 treatments are detected. These
observations were not unexpected considering the fact that NCIH226 cells (EGFR wildtype and p53 mutant) overexpress EGFR which is mainly involved in cell proliferation
pathways instead of cell death pathways. Moreover, the significant G1 phase cell cycle
arrest (Figure 2.8) induced by MMA307 and MMA320 treatment against NCIH226 cells
offer support to the idea that these compounds inhibit cell proliferation rather than induce
cell death. Our findings are in line with studies by Ahmed et al., 2017, Ahmed et al., 2014
and Kutkowska et al., 2017 that report the antiproliferative effects of different estrone
derivatives and anti-EGFRs against distinct cancer cell lines in vitro.

As a result of significant (p < 0.05) G1 phase cell cycle arrest (results are
summarized in Figure 2.8) induced by MMA307 and MMA320 compared to sorafenib, we
analyzed the expression levels of known downstream G1 cell cycle regulators. It has been
reported that Dyrk1B phosphorylates cyclin D1 to promote its ubiquitination and
degradation in the proteasome whereas p21Waf1/Cip1 is stabilized, impacting the G1 phase
cell cycle (Gao et al., 2013; Ashford et al., 2014; Visagie et al., 2017). We observed that
cyclin D1 levels were decreased while p21Waf1/Cip1 levels were increased following
treatment with IC50 amounts of MMA307 and MMA320 in a time-dependent manner
(Figure 2.11 – 2.12). Moreover, treatment with the compounds lead to increased
phosphorylation of cyclin D1 (at phosphorylation site T286) in a time-dependent manner
(Figure 2.11 – 2.12). Cyclin D1 overexpression and p21waf1/cip1 downregulation have been
shown to be important for cancer progression through the G1-S phase transition.

72

Alternatively, phosphorylation of cyclin D1 leads to its turnover, marked by its
ubiquitination and degradation in the proteasome. We report for the first time that,
MMA307 and MMA320 treatments to NCIH226 cells lead to significant downregulation
of cyclin D1 levels, whereas the opposite effect was seen for phospho-cyclin D1 (T286)
and p21waf1/cip1. Aside p21waf1/cip1, Dyrk1B can phosphorylate cyclin D1 on either T286 or
T288 (Gao et al., 2013; Ashford et al., 2014) to arrest damaged tumor cells and to allow
cellular repair in a quiescent state, to ultimately maintain cell survival. Interestingly, the
above studies report that Dyrk1B performs dissimilar functions in arresting G1 phase of the
cell cycle in distinct cancer types. Of note, in a panel of NSCLC cell lines, Dyrk1B
overexpression was associated with colony formation and cell survival whereas its
knockdown leads to opposing effect (Chen et al., 2017; Friedman, 2007; Gao et al., 2009).
Along with other studies by Deng et al., 2006 and Mercer and Friedman, 2006, it has been
suggested that pharmacological inhibition of Dyrk1B sensitizes cancer cells to various
chemotherapeutic agents and maybe an ideal strategy for treating cancers. Consistent with
our findings we observed that MMA320 but not MM307 administration to NCIH226 cells
resulted in Dyrk1B inhibition over the 24 hr time course (Figure 2.11 – 2.12). While the
status of selected G1 phase cell cycle regulators was analyzed in this study, the functions
of other proteins are likely modulated, and therefore, the antiproliferative effects of the
estrone analogs reported here may not be solely due to these proteins alone.

Furthermore, we demonstrated that MMA307 and MMA320 inhibit NCIH226 cell
proliferation by targeting directly the expression levels of EGFR, suppressing its
phosphorylation in a time-dependent manner, followed by inhibition of its downstream
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MAPK (ERK1/2) pathway proteins which are dependent on activated EGFR. Genetic
analyses of various NSCLC revealed that EGFR and its immediate downstream targets, the
MAPK signaling cascades, are frequently overexpressed or mutated during cell
proliferation (Scrima et al., 2017). Constitutive EGFR-mediated signaling and the extent
of ERK1/2 activation are usually correlated with poor prognosis and aggressiveness of
NSCLC, respectively (Scrima et al., 2017). Previous studies by Iida et al., 2013 and
Wheeler et al., 2008 reported that sym004 (a mixture of antibodies) or TKIs impacted
EGFR phosphorylation at tyrosine 1173 (Y1173), and this position is important in
activating the MAPK pathway. Therefore, this phosphorylation site was chosen for further
analysis. We observed that treating NCIH226 cells with MMA320 and MMA307 resulted
in significant inhibition of EGFR and activated EFGR (Y1173) expression levels in a timedependent pattern (Figure 2.9 – 2.10). Concomitantly, activated ERK1/2 pathway proteins,
specifically, BRaf (S445), MEK1/2 (S217/221) and ERK1/2 (T202/Y204) expression
levels (Figure 2.9 – 2.10), were downregulated in a time-dependent manner when
NCIH226 cells were treated with MMA307 and MMA320. Our findings agree with that
made by earlier reports (Abou-Salim et al., 2019; Elgazwi, 2018). It must be acknowledged
that EGFR is a major receptor that triggers numerous downstream pathways, and therefore
it is likely that other proliferation pathways that are activated by EGFR were equally
inhibited by MMA307 and MMA320 administration.

2.5

Conclusion
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We report for the first time the synthesis of novel estrone analogs-a hybrid of
modified Cucs pharmacophore and estrone-base scaffold. These analogs were initially
designed against wild-type EGFR ATP binding site in silico. Among these, MMA307 and
MMA320 demonstrated better potency and binding towards EGFR kinase domain in silico,
and significantly inhibited the proliferation of NCIH226 cells in vitro. The antiproliferation
effect could be ascribed in part to suppression of EGFR and its downstream ERK1/2
signaling pathway, and to the arrest of the G1 phase of the cell cycle. Derivatives of estrone
have been reported to be multitargeted antitumor agents (Solum et al., 2015), and such
types of anticancer agents are of current interest towards the potential development of
remedies against cancer, including NSCLC. The results presented herein provide novel
information on such lead compounds. Taken together, the present study suggest that
estrone analogs may be the potential novel therapeutic agents that can be beneficial to wildtype NSCLC patients.
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Figure 2.1 Molecular docking study of designed estrone analogs against EGFR binding
site (Pdb: 2ITW). Scatter plot of compounds consensus scores generated by VIDA
application.
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Figure 2.2 3D visual representation of MMA307 docked against EGFR binding site (Pdb:
2ITW). There is a cation-π interaction between LYS745A of 2ITW and para-nitrophenyl
aromatic ring of MMA307
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Figure 2.3 3D visual representation of MMA320 docked against EGFR binding site (Pdb:
2ITW). The dashed green line shows hydrogen bonding from the carbonyl-O of MMA320
towards THR854A of 2ITW. Also, there is a cation-π interaction between LYS745A of
2ITW and para-trifluoro phenyl ring of MMA307.
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Figure 2.4 3D visual representation of erlotinib docked against EGFR binding site (Pdb:
2ITW). The dashed green line shows hydrogen bonding from the pyrimidine-N2 of erlotinib
towards MET793A of 2ITW binding site.
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Figure 2.5. 3D visual representation of sorafenib docked against EGFR binding site (Pdb:
2ITW). The dashed green line shows hydrogen bonding from the pyridine-N and methylH of sorafenib towards THR854A as well as from the carbonyl-O towards THR790A of
2ITW binding site.
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Table 2.1 Inhibitory effects of estrone analogs against NCIH226 cell proliferation.

Compound

IC50 (μM)

MMA228
MMA269
MMA270
MMA271(R)
MMA271(S)
MMA287
MMA290
MMA292
MMA300
MMA306
MMA307
MMA308
MMA309
MMA310
MMA311
MMA312
MMA313
MMA316
MMA319
MMA320
MMA321
MMA323
MMA327
MMA334
Sorafenib

99.8 ± 0.28c
10.41 ± 0.46b
> 100c
19.43 ± 0.79d
40.39 ± 1.65b
11.82 ± 0.65b
>100c
>100c
17.41 ± 1.56a
17.42 ± 0.56a
2.88 ± 0.21c
>100c
>100c
>100c
45.46 ± 0.71b
20.64 ± 1.66d
>100c
>100c
>100c
9.68 ± 0.24b
14.57 ± 0.31b
>100c
>100c
42.02 ± 1.57b
20.62 ± 1.32
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Figure 2.7 Growth inhibitory effects on NCIH226 after treatment with IC50 values of
estrone analogs. (A) Morphological changes in NCIH226 cells after treatment with 0.05%
DMSO, MMA320, MMA307 and sorafenib. Images were acquired with ×4 objective lens
of Evos XL cell imaging system (ThermoFisher Scientific), scale bar = 200 µm. (B).
Trypan blue cell counting after 24 hrs. The number of cells was determined by counting
and expressed as mean % ± SD of two independent experiments with n=2 per condition in
each experiment.
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Figure 2.8 Estrone analogs exposure resulted in G1-phase cell cycle arrest. NCIH226 cells
were treated with IC50 values of estrone analogs and analyzed after 48 hrs by flow
cytometry. (A) Distribution of cells in distinct phases of the cell cycle. MMA320 shows
the highest arrest of G0/G1 phase of the cell cycle compared to the negative control, DMSO.
(B) The bar graphs show Mean ± SD of the percentages of NCIH226 cells in the indicated
phases of the cell cycle (G0/G1, S and G2/ M). At least three independent experiments were
performed. *p < 0.05, **p < 0.01, ***p < 0.001 significant differences in cell cycle arrest
compared to DMSO control.
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Figure 2.9 EGFR and multiple MAPK-ERK1/2 effector molecules are inhibited in
NCIH226 cells by MMA307 treatment. (A) MMA307 inhibited EGFR and pEGFR, as well
as multiple downstream MAPK-ERK1/2 effector molecules, detected through In Cell
Western (ICW) assay. After treatment with MMA307 (2.88 μM), fixed cells were
incubated with specific antibodies for each protein. The cells were washed and incubated
with DyLight conjugated (680 or 800 nm) detection antibodies, and plates scanned with
LICOR Odyssey® Fc imaging system to measure the levels of total and phosphorylated
proteins. Quantitation of proteins was completed using scanned images from Fiji software.
(B) Cell extracts were also fractionated on SDS-PAGE, followed by immunoblot analysis
for the indicated proteins. β-Actin was examined as a loading control for each immunoblot
analysis. (C-F) Data points are represented as the mean of duplicate and SD of two
independent experiments.
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Figure 2.10 Effects of MMA320 treatments on EGFR and multiple MAPK-ERK1/2
effector molecules in NCIH226 cells. (A) Cells were treated for indicated times with 9.68
μM MMA320. Cell lysates were analyzed by SDS-PAGE, transferred to nitrocellulose
membranes and use of the corresponding primary antibodies against specific proteins and
GAPDH as loading controls. Blots are representative examples of at least two independent
experiments. LICOR Odyssey® Fc imaging system analysis of bands comparing the
relative levels of proteins after time-course treatment with MMA320 as compared to
DMSO control. (B-E) Bar graphs are means ± SD from at least two independent
experiments.
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Figure 2.11 Effects on G1 phase cell cycle regulators after treatment with MMA307 in
NCIH226 cells. (A-B) Cells were treated for indicated times with 2.88 μM MMA307. Cell
lysates or fixed cells were analyzed by western blot or ICW and use of the corresponding
primary antibodies against specific proteins and β-Actin or GAPDH as loading controls.
LICOR Odyssey® Fc imaging system analysis of bands comparing the relative levels of
proteins after time-course treatment with MMA320 as compared to DMSO control. Blots
or ICW images are representative examples of at least two independent experiments. (CD) Line graphs are means ± SD from at least two independent experiments.
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Figure 2.12 Effects on G1 phase cell cycle regulators after treatment with MMA320 in
NCIH226 cells. (A) Cells were treated for indicated times with 9.68 μM MMA320 for
indicated times. Cell lysates were analyzed by SDS-PAGE gels, transferred to
nitrocellulose membranes and use of the corresponding primary antibodies against
Dyrk1B, cyclin D1, p-cyclin D1, p21waf1/cip1 and β-actin as loading controls. LICOR
Odyssey® Fc imaging system analysis of bands comparing the relative levels of proteins
after time-course treatment with MMA320 as compared to DMSO control. Blot images are
representative examples of at least two independent experiments. (B) Line graphs are
means ± SD from at least two independent experiments.
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Chapter 3

Estrone hybrids with modified cucurbitacin pharmacophores induce growth
inhibition and apoptosis via suppressing EGFR, Akt/mTOR and ERK1/2 pathways
in triple negative breast cancer cells.
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3.1

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast cancer with an aggressive
phenotype which shows high metastatic capability and poor prognosis. The aggressive
behavior of TNBC may involve aberrant EGFR expression and activation of its
downstream PI3K/Akt/mTOR and RAF/ERK signaling which has received considerable
attention as druggable targets in recent times. Currently, no targeted therapy has been
approved for treating TNBC. Previous studies from our research group showed that estrone
analogs with cucurbitacin pharmacophores and nitric oxide releasing properties inhibited
the proliferation of several type of cancers. In this study, we report that novel estrone
analogs with modified cucurbitacin pharmacophores exhibited cytotoxic killing towards
TNBC cells through multiple mechanisms, inhibition of cell proliferation and induction of
mitochondrial apoptosis. Molecular docking studies were carried out with OpenEye
software. The MTT cell viability assay was used to perform cytotoxicity studies.
Morphological changes and cell cycle arrest were carried out by microscopy and flow
cytometric techniques, respectively. Annexin V assay was used to evaluate initial apoptosis
induction in MDA-MB-468 cells, and In-cell western assay was used to detect the
expression levels of apoptotic, cell cycle and EGFR and its downstream AKT and ERK1/2
pathways associated proteins. We demonstrated that MMA307 and MMA321 showed
strong potency towards the EGFR kinase domain (pdb code: 1M17) in silico and exhibited
cation-π and hydrogen bonding interactions towards amino acid residues within the ATP
binding site. MMA307 was over tenfold more cytotoxic than sorafenib when dosed to
MDA-MB-468 cells and MMA321 was almost twenty-fold more potent than sorafenib.
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Moreover, condensed nuclei with fragmented chromatin, phosphatidylserine flip and
modulated expression of proteins within the intrinsic apoptosis pathway (Apaf1,
cytochrome c, caspases 3 and 9) confirms mitochondrial apoptosis and suggest MMA307
and MMA321 induced apoptosis via caspase-dependent pathways. Also, MMA307 and
MMA321 downregulated cyclin D1 expression levels contributing to G1 phase cell cycle
arrest. Furthermore, both compounds inhibited the expression of EGFR and activated
EGFR (Y1068); Activated proteins within the RAF/ERK and AKT/mTOR pathways were
downregulated upon MMA307 and MMA321 treatment. Particularly, pARaf, pERK1/2,
pAKT, pmTOR and p70S6Kα were all suppressed. Taken together, we report for the first
time that estrone analogs with modified cucurbitacin pharmacophores may be an effective
therapy for TNBC, which urgently needs novel treatment options. Further studies are
needed to develop these novel candidates as targeted agents for TNBC.

Keywords: TNBC; EGFR; Estrone analogs; MDA-MB-468; Apoptosis; Cell cycle
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3.2

Introduction

Breast cancer is the most common invasive cancer in women globally and the leading cause
of cancer‑related death (Bray et al., 2018). Breast cancers can be categorized into four main
subtypes in accordance to the pattern of genetic profiling. Two are derived from hormone
receptor expression, thus estrogen receptor (ER)‑positive tumors, luminal A and B, and the
remaining two are derived from lack of hormone receptor expression, thus ER‑negative
tumors, basal‑like and HER2 positive (Berrocal, 2017). Triple-negative breast cancer
(TNBC) is a basal‑like subtype of breast cancer that accounts for about 20% of all breast
cancers (Dai et al., 2015; Uscanga-Perales et al., 2016; Lee and Djamgoz, 2018). In
comparison with other breast cancer subtypes, TNBC is a heterogeneous disease with a
higher metastasis rate, worse prognosis, and higher relapse risk (Uscanga-Perales et al.,
2016, Podo et al., 2016). Also, brain metastasis is mainly the results of TNBC progression
(Feng et al, 2018). This disease stage has no effective therapeutic option partially due to
the poor penetration of drugs across the blood-brain barrier. Therefore, TNBC has attracted
increasing amounts of attention in oncology research. Currently, the major therapies for
breast cancer include surgery, radiation therapy, hormone therapy and chemotherapy.
Surgery and radiotherapy are local therapy methods for the treatment of cancer. Because
of the high metastasis and relapse rates of TNBC, new therapeutic modalities need to be
discovered for TNBC treatment. Contrary to this, TNBC cannot be treated by hormone
therapy because it lacks or has low expression of estrogen receptor (ER), progesterone
receptor, and human epidermal growth factor receptor 2 (HER2) (Ma et al., 2017). Despite

102

several possible targeted agents been studied in the last two decades, currently, there are
no targeted therapies approved by the FDA and other agencies around the globe for treating
TNBC (Yue et al, 2018). Hence, standard chemotherapy, especially anthracycline‑based
agents, remains the first option of current TNBC treatment strategies (Cortazar et al.,
2014), but there is still a substantial risk for recurrence and aggressive disease progression
(Székely et al., 2017; Wahba and El-Hadaad, 2015). Thus, it is urgent to discover highly
effective and low toxic targeted treatment strategies for TNBC.

Natural products are often regarded as sources of phytochemicals or leads for the discovery
of novel drugs. Phytochemicals are naturally occurring secondary metabolites-biologically
active compounds found in plants, animals, microorganisms and marine organisms which
have capabilities of inhibiting various diseases including cancer. Notable examples include
the vinca alkaloids vincristine and vinblastine isolated from Catharanthus roseus, as well
as taxol isolated from Taxus brevifolia, for the treatment of various cancers (Acheampong
et al, 2017; Acheampong et al, 2015; Larbie et al, 2015). In the face of worldwide disease
challenges, natural products research and development potentially play a key function in
innovative drug discovery. About 33% of FDA-approved drugs over the past two decades
are based on natural products or their derivatives and these have transformed medicine
(Thomford et al, 2018). In particular, Stander et al, 2011, Botes et al, 2018, report that 2Methoxyestradiol (2ME), an endogenous metabolite of 17β-estradiol, and its
sulphamoylated derivative (Visagie et al, 2013; Verwey et al, 2016; van Vuuren et al,
2019) possess both antiangiogenic and anti-breast cancer effects in vitro and in vivo.
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However, 17β-estradiol promotes the proliferation of various cancers (Verwey et al, 2016).
This suggests that estradiol may be a privileged scaffold upon which modifications can be
done to generate lead candidates with improved potency and pharmacokinetic properties
as well as reduced toxicities. In our research group, estrone, an isomer of estradiol, is used
as a starting material to synthesize novel estrone analogs. Many of our estrone derivatives,
especially those bearing cucurbitacin side chains have been documented to exhibit potent
cytotoxic effects against distinct cancers (Ahmed et al, 2017; Elshaier et al, 2017; Ahmed
et al, 2014; Kopel et al, 2013). Also, Sara et al, 2018 reported on the cytotoxic effect and
EGFR/MAPK pathway suppression capabilities by the novel estrone analogs with
cucurbitacin side chains against wild-type and resistant HepG2 cell lines. In addition, Amr
and colleagues, 2019, reported that novel estrogen analogs effectively bind to EGFR in
vitro and in vivo and were cytotoxic against MCF-7 cells but not towards MCF-10A cells
alluding to their selectivity.

In the current research, we showed that several estrone analogs were effective in inducing
growth inhibition, cell cycle arrest and apoptosis in the TNBC model MDA‑MB‑468 cells.
Also, we determined the effect of MMA307 and MMA321 on EGFR and its downstream
PI3K/Akt/mTOR (PAM) and RAF/ERK pathways, because both represent the main
signaling pathways responsible for cell metabolism, survival and proliferation and are often
activated in TNBC (Ignacio et al., 2018; Chen and Costa, 2018; Foidart et al., 2019). We
revealed that MMA307 and MMA321 suppression of MDA-MB-468 cells growth could
be as a result of multiple factors including inhibition of EGFR and its downstream PAM
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and MAPK pathways; induction of mitochondrial apoptosis and suppression of cell cycle
progression.

3.3

3.3.1

Materials and methods

Reagents and chemicals

Antibodies against EGF Receptor (D38B1) XP®, Phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) (197G2), Cyclin D1 (92G2), Phospho-Akt (Ser473) were purchased from
Cell Signaling Technology (Danvers, MA, USA); goat anti-rabbit and goat anti-mouse
horseradish peroxidase conjugate (HRP) secondary antibodies, phospho-cyclin D1
(Thr286) (A537487), Phospho-A-Raf (Ser299) were from Thermo Fisher Scientific
(Waltham, MA, USA); Phospho-EGF Receptor (Tyr1068), Phospho-p70S6 Kinase α,
Dyrk1B, caspase 9, caspase 3, PARP1, cleaved PARP1, Bcl-2, APAF1, cytochrome C and
GAPDH were from Santa Cruz Biotechnology Inc. (Dallas, Texas, USA). Phosphate
buffered saline (PBS) and trypan blue solution were from Thermo Fisher Scientific
(Waltham, MA, USA). RealTime-Glo™ Annexin V apoptosis and necrosis assay (JA1011)
kit was from Promega (Madison, WI, USA). PI/RNase staining buffer was purchased from
BD Biosciences (San Jose, CA, USA). Compounds cytotoxicity was evaluated through
measurement of mitochondrial dehydrogenase activities with 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) reagent (Sigma-Aldrich, St. Louis, MO, USA).
Hoechst 33342 stain for evaluating chromatin condensation and nuclear fragmentation was
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purchased from Thermo Fisher Scientific (Waltham, MA, USA). Sorafenib (positive
control) (Selleckchem, Houston, TX, USA) and novel triazole derived estrone analogs
were dissolved in dimethyl sulfoxide (DMSO) (Fisher Chemical/Fisher Scientific).
Western Lightning Plus-ECL, Enhanced Chemiluminescence Substrate for protein
detection was purchased from PerkinElmer (Waltham, Massachusetts, USA). All other
chemicals were of biological and analytical grade.

3.3.2

Design and synthesis of estrone analogs

3.3.2.1 Molecular modeling

Fitting novel estrone analogs into the 3D X-ray structure of EGFR kinase domain (PDB
code: 1M17) was carried out using the FRED application (version 2.2.5) as implemented
through the graphical user interface of OpenEye® software. The 3D structure of the above
protein was downloaded from Protein Data Bank (pdb) and prepared with the make
receptor software. The three-dimensional structures of the estrone analogs were
constructed using Chem. 3D ultra 12.0 software [Chemical Structure Drawing Standard;
Cambridge Soft corporation, USA (2010)], then they were energetically minimized with
MMFF94 application with 5000 iterations and minimum RMS gradient of 0.10. All bound
water molecules and ligands were eliminated from the proteins. Furthermore, multiconformers were generated using OMEGA application (version 2.5.1.4) and the VIDA
application (version 4.1.2) was used as a visualization tool to show the potential binding
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affinity and binding interactions of the ligands to the receptor (Elshaier et al, 2017). This
software package generates consensus scoring which is a filtering process to obtain virtual
binding affinity. The lower the consensus score, the better binding affinity of the ligands
towards the receptor.
3.3.2.2 Synthesis of MMA307 and MMA320

3.3.2.2.1 General procedure for the preparation of MMA307

Steps 1 to 9 has been previously reported by our research group (Ahmed et al, 2014; Kopel
et al, 2013). Preparation of 10 was carried out as follows: 0.15 g of 9 was dissolved in N,
N-dimethylacetamide (0.8 mL) and incubated with sulfamoyl chloride (0.12 g, 0.945
mmol) at 0ºC. Subsequently, the reaction mixture was stirred at room temperature for 18
hrs and the resulting solution extracted with 1:1 mixture of ethyl acetate and water. The
residue was purified using silica gel column chromatography (ethyl acetate: n-hexane, 3:7)
to isolate compound 10 which was labeled as MMA307 (0.16 g, 91%). MMA307 was
characterized by 1H and

13

C NMR and high-resolution mass spectroscopies (Mahnashi,

2017).
MMA307 1H NMR (600 MHz, Chloroform-d) δ 8.21 – 8.18 (m, 2H), 7.77 (d, J = 15.7
Hz, 1H), 7.71 – 7.67 (m, 2H), 7.25 – 7.21 (m, 1H), 7.10 (d, J = 15.7 Hz, 1H), 7.01 (dd, J =
8.6, 2.6 Hz, 1H), 6.95 (d, J = 2.6 Hz, 1H), 5.03 (s, 2H), 3.98 – 3.89 (m, 1H), 3.83 (s, 1H),
2.78 (qd, J = 10.4, 9.7, 4.3 Hz, 2H), 2.29 – 2.21 (m, 2H), 2.16 (dq, J = 12.0, 4.2 Hz, 1H),
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1.84 – 1.77 (m, 2H), 1.64 – 1.56 (m, 2H), 1.56 – 1.53 (m, 2H), 1.50 (s, 3H), 1.41 – 1.31
(m, 2H), 0.88 (s, 3H).
MMA307

13C

NMR (151 MHz, CDCl3) δ 203.04 (C21), 148.81 (C3), 147.90 (C27),

142.60 (C23), 140.35 (C24), 139.64 (C5), 138.92 (C10), 129.26 (C25, C29), 126.73 (C1),
124.25 (C26,C28), 122.29 (C22), 121.93 (C4), 118.95 (C2), 79.54 (C19), 55.66 (C14),
54.98 (C17), 44.31 (C8), 43.97 (C13), 40.51 (C12), 37.65 (C15), 29.51 (C6), 27.26 (C11),
26.43 (C7), 24.22 (C9), 23.64 (C20), 22.09 (C16), 13.65 (C18).
HR-FT-MS calcd for C29H34O7N2SNa 577.1979 found 577.19790.

3.3.2.2.2 General procedure for the preparation of MMA321

Steps 1 to 9 has been previously reported by our research group (Ahmed et al, 2014; Kopel
et al, 2013). Synthesis of 10 was carried out as follows: to a stirred solution of the 9 (0.4g,
1.13 mmol), a mixture of tetrahydrofuran and lithium diisopropylamine (LDA) (2.034mL,
4.068 mmol) were added and the reaction kept at -78 ºC. Afterwards, the reaction mixture
was initially stirred for 1 hr, before para-nitrobenzene (0.242mL, 2.26mmol) dissolved in
THF added and the resulting mixture warmed to room temperature for 24 hrs.
Subsequently, the reaction was quenched with ammonium chloride and the aqueous layer
extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtrated, and
concentrated under vacuum. Silica gel column chromatography was used to purify the
crude material (ethyl acetate: n-hexane, 1:9) to obtain 10 (0.29g, 52.7%). Pure compound
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10 was characterized by NMR and mass spectroscopies and labeled as MMA321
(Mahnashi, 2017).
MMA321

1

H NMR (400 MHz, Chloroform-d) δ 8.14 (m, 2H), 7.75 (m, 1H), 7.61 (m,

2H), 7.12 (s, 1H), 7.08 – 6.96 (m, 2H), 6.59 – 6.52 (m, 1H), 6.49 (d, 1H), 5.95 (d, 1H),
4.24 (s, 1H), 3.64 (s, 3H), 2.79- 2.73 (m, 2H), 2.20-2.10 (m, 2H), 2.01 (m, 1H), 1.79 (d,
1H), 1.48 – 1.35 (m, 1H), 1.32 – 1.13 (m, 3H), 1.08 (m, 1H), 0.94 (s, 3H), 0.85- 0.76 (m,
4H).
MMA321

13

C NMR (101 MHz, Chloroform-d) δ 200.45, 157.40, 154.95, 148.73, 141.74,

140.35, 137.79, 132.62, 129.97, 129.24, 125.96, 124.20, 122.58, 113.78, 111.35, 78.89,
57.48, 55.14, 47.83, 43.91, 37.05, 34.67, 34.54, 31.60, 31.24, 29.65, 27.57, 26.25, 25.29,
25.18, 22.67, 17.19, 14.16.
HR-FT-MS calcd for C30H33O5N1Na1 510.2251 found 510.22454.

3.3.3

Cell culture

MDA-MB-468 (a model for TNBC with amplified EGFR) was a kind gift from Dr. Rachel
Willand Charnley (South Dakota State University, Department of Chemistry and
Biochemistry). The cells were cultured in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% (v/v) fetal bovine serum (FBS), antibiotic-antimycotic (Gibco™,
ThermoFisher Scientific) at 37˚C equilibrated with 5% (v/v) CO2 in humidified air. The
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cells for the assays were detached using a solution of trypsin with EDTA (ThermoFisher
Scientific).

3.3.3.1 Cytotoxicity assay

3.3.3.1.1 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
Assay

The effect of novel synthetic estrone analogs on cell viability was tested with MTT reagent
as described by Wang et al, 2010, with slight modifications. Briefly, to measure
mitochondrial dehydrogenase activities, cells were seeded into wells on 96-well plates at
an initial density of 30, 000 cells per well. After overnight incubation, cells were treated
with different concentrations of compounds in a dose range of 0 - 100 μM. The final DMSO
concentration was 0.05%. After 48 hrs of incubation, 20 μL of MTT reagent (5 mg/mL)
was added to each well and the formed formazan crystals were dissolved in 250 μL of
dimethyl sulfoxide (DMSO). Four independent experiments were completed to determine
the mean optical density referred to as cell viability, using a Hidex Sense Beta Plus plate
reader (Turku, Finland). Cell viability was expressed as a percentage of DMSO-treated
controls.

3.3.3.2 Flow cytometry for cell cycle analysis

110

MDA-MB-468 cells were seeded into six-well plates at a concentration of 300, 000 cells/
well and allowed to attach in culture overnight, then treated with IC50 molarity of
compounds or positive control (sorafenib) for 48 h. Afterward, cells were washed with PBS
and harvested. Cell cycle analysis was investigated by adding propidium iodide (PI) stain
(Thermo Fisher Scientific) to 1 mL of cell suspension. Briefly, harvested cells were fixed
in 70% ethanol and incubated at 4ºC for 4hrs. Subsequently, the cells were cleaned of
alcohol and stained with RNase free PI solution, the cell suspension was incubated in the
dark for 45 minutes at room temperature. The samples were analyzed by flow cytometry
and compared to DMSO-treated cells. All these experiments were performed on
CytoFLEX flow cytometer, serial no. AW35216 (Beckman Coulter Life Sciences,
Indianapolis, IN, USA) using CyExpert software, version 1.2.

3.3.3.3 Apoptosis analysis

3.3.3.3.1 Annexin V assay

The annexin v assay was performed in accordance with the manufacturers’ protocol with
slight modifications. Briefly, MDA-MB-468 cells were seeded into wells on a 96-white
plate with a clear bottom at an initial density of 30,000 cells for overnight attachment.
Afterward, the cells were incubated with the IC50 concentrations of compounds for 12 hrs.
Subsequently, the RealTime-Glo™ Annexin V Apoptosis reagent (Promega, Madison, WI)
was prepared (sequentially mix Annexin NanoBiT® Substrate, CaCl2, Annexin V-SmBiT
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and Annexin V-LgBiT in a prewarmed media) and added to the reaction set up before
incubating for additional 1 hr. Luminescence was measured afterward using Hidex Sense
Beta Plus plate reader (Turku, Finland). Apoptosis was expressed as a percentage relative
to DMSO-treated controls.

3.3.3.3.2 Morphological analysis with fluorescence microscopy

To further evaluate the apoptotic activity of the estrone analogs, nuclear staining with the
DNA-binding dye Hoechst-33342 was performed in accordance with the manufacturers’
protocol. In brief, MDA-MB-468 cells were plated into wells on 96-well plates and treated
with IC50 concentrations of compounds for 12 hrs. Cells were washed with PBS and
incubated with Hoechst-33342 (10μg/mL) for 15 min in the dark, then images were
acquired using Cytation 3 imaging multi-mode reader (BioTek Instruments, Inc., Waltham,
MA, USA) with 4× objective lens (excitation 352 nm, emission 461 nm). Apoptotic cells
were identified by condensation of chromatin and fragmentation of nuclei with Gen5
software version 3.03.

3.3.3.4 Protein expression analysis

3.3.3.4.1 In-Cell Western (ICW) Assay
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Proteins involved in apoptosis, cell cycle progression, EGFR, and its downstream MAP
kinase and Akt pathways were quantified by ICW. This technique was carried out in
accordance with the manufacturer’s instruction with slight modifications. Briefly, about
50,000 cells per well were seeded into 96-well white-walled plate with clear bottom for
overnight attachment. Afterward cells were washed three times with PBS and depleted of
serum for six hours. Cells were then treated with varying concentrations of compounds in
serum-free media for six hours before stimulating with 100nM of EGF for one hour.
Subsequently, cells were fixed with 3.7% formaldehyde solution, permeabilized with 0.1%
Triton X-100 solution and blocked with fish gel buffer (1×) prior to primary antibody
addition. Wells were then incubated with the relevant antibodies EGF Receptor (D38B1)
XP®, Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (197G2), Cyclin D1 (92G2),
Phospho-Akt (Ser473), Phospho-A-Raf (Ser299), Phospho-EGF Receptor (Tyr1068),
Phospho-p70S6 Kinase α, caspase 9, caspase 3, PARP1, cleaved PARP1, Bcl-2, APAF1,
cytochrome C and GAPDH (loading control) overnight followed by an hour incubation
with goat anti-mouse or goat anti-rabbit horseradish peroxidase conjugated secondary
antibodies. Finally, the cell mixture was incubated with enhanced chemiluminescence
substrate (Western Lightning Plus-ECL) for a few minutes before chemiluminescence was
measured using Hidex Sense Beta Plus plate reader (Turku, Finland). Protein expression
levels were normalized to the housekeeping gene, GAPDH, and expressed as a percentage.

3.3.4

Statistical Analysis
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Microsoft® Excel® for Windows, version 16.0., was used for the calculation of mean and
standard deviation values of different experiments and plotting of bar or line graphs. Mean
IC50 values were compared by one-way analysis of variance (ANOVA) and multiple
comparisons were done by the Dunnett Test using GraphPad Prism 5.01 (San Diego, USA)
and values with p < 0.01 or p < 0.001 were considered statistically significant.
3.4

3.4.1

Results

Docking simulations

To demonstrate whether the designed estrone analogs can target EGFR dependent breast
cancers, an initial in silico molecular docking studies were carried out by fitting the
designed analogs and reference compound (erlotinib) into the ATP binding site of the
EGFR kinase domain (PDB codes: 1M17). The obtained results were plotted as a linescatter graph (Figure 3.1), which mainly displays the corresponding consensus scores of
the molecular docking studies. Compared with the reference drug, erlotinib, it was clearly
observed that most estrone analogs showed lower consensus scores (a measure of better
binding and improved potency) when fitted into the EGFR kinase domain. Furthermore,
the binding mode of MMA307 and MMA321 revealed that MMA307 fitted into the
hydrophobic pocket of the EGFR kinase domain and demonstrated hydrophobic interaction
towards the ATP binding site. However, MMA321 demonstrated hydrogen bonding
towards THR830A, ASP831A and LYS721A residues within the ATP binding site of
1M17 (Figures 3.3 – 3.4). Also, these compounds exhibited potent cytotoxic effects against
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MDA-MB-468 cells in vitro compared to sorafenib. The addition of a sulfamoyl moiety to
compound 9 afforded 10 (MMA307) in 91% yield after column chromatography (scheme
3.1), and the addition of para-nitrobenzene to the hyroxyl methyl ketone diastereomeric
mixture yielded 52.7% of MMA321 after purification with silica gel column
chromatography (Scheme 3.2). These pure compounds were characterized by NMR and
mass spectrometry techniques with the 1H and

13

C chemical shifts as well as accurate

masses reported above. In terms of IUPAC nomenclature, MMA307 was named as
(8S,9S,13S,14S,17S)-7,8,9,11,12,13,14,15,16,17-decahydro-17-((R,E)-2-hydroxy-5-(4nitrophenyl)-3-oxopent-4-en-2-yl)-13-methyl-6H-cyclopenta[a]phenanthren-3-yl
sulfamate

and

MMA321

named

as

4-Hydroxy-4-(3-methoxy-13-methyl-

7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl)-1-(4-nitrophenyl)-pent-1-en-3-one (Figure 3.5).

3.4.2

Estrone analogs exhibit cytotoxic effects against MDA-MB-468 cells

To determine the cytotoxic effects of the estrone analogs against TNBC cell lines, the
viability of MDA-MB-468 cells initially treated with a dose range of 0 – 100 µM was
analyzed using the MTT cell viability assay after 48 hrs. Overall, the compounds did show
a significant cytotoxic effect toward the MDA-MB-468 cells within the dose range tested
after 48 hrs and therefore IC50 values were calculated. Most of the compounds were very
effective than the positive control-sorafenib in exhibiting cytotoxic killing towards MDAMB-468 cells. Particularly, MMA300, MMA307, MMA320 and MMA321 recorded IC50
concentrations of 0.89 ± 0.10, 0.85 ± 0.00, 1.71 ± 0.01 and 0.56 ± 0.01 μM, respectively
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compared to sorafenib IC50 molarity of 10.09 ± 0.68 μM (Table 3.1). MMA321 was almost
twenty fold more potent whereas MMA307 was more than tenfold more potent compared
to sorafenib in exhibiting their cytotoxic effect. Therefore, in the subsequent experiments
the IC50 concentrations of MMA307 and MMA321, a highly effective and low toxicity
dose was used. Mechanisms pertaining to programmed cell death, apoptosis, and that
involved in inhibition of proliferation were investigated.

3.4.3

Estrone analogs induce apoptosis in TNBC cells

3.4.3.1 RealTime-Glo™ Annexin V assay

The apoptosis-inducing effect of MMA307 and MMA321 in MDA-MB-468 cells were
evaluated by RealTime-Glo™ Annexin V apoptosis and necrosis luminescent assay. The
detection reagent contains Annexin V-LgBiT and Annexin V-SmBiT (NanoBiT) fusion
proteins and a profluorescent DNA dye. In healthy cells, most of the phosphatidylserine
(PS) is confined to the inner leaflets of the cell membrane, fewer fusion proteins bind to
PS and less luminescence is recorded. In apoptotic cells, PS is exposed to the outer leaflet
of the cell membrane, more fusion proteins bind to PS and increased luminescence is
measured. Increased luminescence corresponds to increased apoptosis. Exposing MDAMB-468 cells to MMA307 and MMA321, resulted in increased apoptosis in a dosedependent manner (Figure 3.6 A). Notably, both compounds induced apoptosis in MDAMB-468 cells within 12 hrs of drug incubation similar to the positive control, camptothecin.
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3.4.3.2 Morphological analysis with fluorescence microscopy

The morphological changes in cell nuclei of MDA-MB-468 cells within 12 hrs after
treatment with MMA307 and MMA321 showed significant shape alterations when
compared to 0.05% DMSO control. As shown in Figure 3.6 B, the control or untreated
cells appeared as intact oval shape and the nuclei were stained with a less bright blue
fluorescence (due to the Hoechst 33342 dye). Cells treated with tested compounds
exhibited typical features of apoptosis such as cell shrinkage, chromatin condensation, and
nuclear fragmentation in multiple, segregated bodies, the formation of apoptotic bodies,
and cell decrement. The apoptotic nuclei clearly showed highly condensed or fragmented
chromatin that was uniformLy fluorescent. MMA307 and MMA321, as well as sorafenib
treatments, resulted in increased apoptotic cells (condensed chromatin, indicated by
arrows) compared to the DMSO control.

3.4.3.3 Estrone analogs induce apoptosis via the mitochondrial pathway

To further study the effects of MMA307 and MMA321 on apoptosis, ICW assay was
performed to detect changes in protein expression involved in the apoptosis pathway. As
shown in Figure 4 and 5, exposure of MDA-MB-468 cells to the compounds resulted in
increased expressions of cytochrome C and apoptotic protease activating factor 1 (APAF1),
which are markers of mitochondrial apoptosis. Furthermore, we observed decreased
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expression of B-Cell Lymphoma 2 (Bcl-2) protein when TNBC cells were treated with
both compounds (Figure 3.7). Also, when the compounds were administered to cells an
elevated expression caspase-3 and -9 were increased post-treatment with MMA307 and
MMA321 (Figure 3.8). All these results indicate that MMA307 and MMA321 could
effectively induce apoptosis in MDA-MB-468 cells via the mitochondrial pathway and in
a caspase-dependent manner.

3.4.4

Estrone analogs inhibit the proliferation of MDA-MB-468 cells through G1
phase cell cycle arrest

To elucidate the antiproliferative effects of MMA307 and MMA321 on MDA-MB-468
cells, the cell cycle distribution was the first mechanism examined by propidium iodide
(PI) stain and distinct populations analyzed by flow cytometry. Cell-cycle population
distribution of MDA-MB-468 cells exposed to DMSO (Figure 3.9 A) showed an average
of 3% in the G0/G1 phase, 1.5% in the S phase, and 95.5% in the G2/M phase. Treating
MDA-MB-468 cells with sorafenib resulted in enrichment of cells within G0/G1 phase,
15.43%. Also, accumulation of cells in the S phase was 4.35% and G2/M phase 81.59%.
Exposure of cells to MMA307 resulted in significant accumulation of cells within G0/G1
phase, an average of 42.3%; there was decrease enrichment of cells in the G2/M phase, an
average of 47.2% was observed. Similarly, exposure of MDA-MB-468 cells to MMA321
resulted in significant enrichment of cells within the G0/G1 phase of the cell cycle. It
arrested an average of 58.11% of cells in the G0/G1 phase and a lower number of cells (an
average of 29%) in the G2/M phase.
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3.4.4.1 G1 phase cell cycle associated proteins are modulated post estrone analogs
exposure

As a result of the significant (p < 0.05) cell cycle arrest induced by the estrone analogs, we
analyzed the expression levels of known G0/G1 phase cell cycle proteins. In-Cell Western
approach was adopted to establish our findings. Cyclin D1 plays a vital role in regulating
the progression of cell cycle within the G1 phase. We observed that MMA307 and
MMA321 administration towards MDA-MB-468 cells resulted in the suppression of cyclin
D1 expression levels in a concentration-dependent manner within 12 hrs (Figure 3.9B).
These findings are in line with the significant G0/G1 phase cell cycle arrest recorded above.

3.4.5

EGFR and its downstream signaling pathways are inhibited after TNBC
exposure to estrone analogs

We evaluated the expression levels of total and activated (phosphorylated) forms of EGFR
by ICW (Figure 3.10). Higher levels of EGFR were detected in the EGF only treated cells
compared to the compound plus EGF treated cells, depicting EGFR downregulation.
Similarly, levels of phosphorylated EGFR (Y1068) were also increased in the EGF only
treated cells compared to EGF plus compound treated cells. EGFR and phosphorylated
EGFR (Y1068) expression levels were downregulated in a concentration-dependent
manner

post

MMA307

and

MMA321

exposure.

The

purpose

of

EGFR

autophosphorylation within tyrosine residues, especially Y1173 and Y1068, is to activate
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signaling pathways such as PI3K/AKT and RAS/MAPK pathways involved in cell
proliferation, survival and angiogenesis (Romano et al, 2011). Next we investigated the
activation of these pathways by quantifying activated (phosphorylated) forms of ERK1/2and AKT-associated pathway proteins. Decreased amounts of phospho-ARaf (S299) and
phospho-ERK1/2 (T202/Y204) (Figure 7) were clearly detected in MDA-MB-468 cells
when exposed to MMA307 and MMA321 together with 100 nM of EGF in a dosedependent manner. Similarly, phospho-AKT (S473), phospho-mTOR (S2448) and
phospho-p70S6Kα (S411) expression levels (Figure 3.11) were downregulated in
concentration-dependent manner in the presence of estrone analogs and 100nM of EGF.
Based on the low expression levels of activated ERK- and AKT-associated proteins,
RAS/MAPK and PI3K/AKT signaling pathways were downregulated in MDA-MB-468
cell line upon estrone analogs treatment. This could be one of the key reasons underlying
the observed growth inhibition in TNBC cells.

3.5

Discussion

This study revealed that estrone analogs exhibit cytotoxic killing in TNBC cells through
inhibition of cell proliferation and induction of apoptosis. The mechanisms of
antiproliferation involved cell cycle arrest, suppression of EGFR and blocking of its
downstream RAS/MAPK and PI3K/AKT pathways whereas the mechanism of cell death
studied was that of mitochondrial apoptosis. Therefore, MMA307 and MMA321 have a
good antitumor effect against TNBC cells in vitro.
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Installing various modified cucurbitacin pharmacophores and other moieties onto the
estrone scaffold yielded unique hybrid analogs. Among these MMA307, containing
sulfamoyl and paranitrophenyl groups, and MMA321, possessing paranitrophenyl and
methoxy substituents, exhibited acceptable potency in silico and stronger cytotoxic effects
in vitro. Previous studies by Stamos et al, 2002 suggested that hydrogen bonding towards
the amino acid residue, MET 769A, alongside other hydrophobic interactions in the EGFR
kinase domain are important for a drug to elicit cytotoxic effects. Our findings revealed
that the reference compound, erlotinib, showed hydrogen bonding from the pyrimidine-N2
towards MET 769A (Figure 3.2) and registered a lower consensus score (a measure of
effective binding and drug potency). However, examining the analog MMA307, enriched
with pharmacophores capable of donating and accepting hydrogen bonds within the EGFR
kinase domain, we observed hydrophobic-hydrophobic (cation-π) interactions between the
steroidal aromatic ring and the amino acid residue, LYS721A (Figure 3.3). Also, analyzing
the analog MMA321 within the EGFR binding site revealed hydrogen bonding from the
nitro-O on the substituent group towards the amino acid residue THR830A (Figure 3.4).
The hydrogen bonding exhibited by MMA321 towards THR830A and the cation-π
interactions exhibited by MMA307 towards LYS721A demonstrate a strong and unique
binding mode and suggest that interactions with THR830A and LYS721A residues in the
EGFR kinase domain may be key in the estrone analogs achieving in vitro and in vivo drug
potency. These results could provide a molecular level foundation to illustrate that
MMA307 and MMA320 can bind well towards the EGFR kinase active site. These findings
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are further supported by their lower IC50 concentrations compared to sorafenib from the
cell viability assay in vitro.

Estrone analogs have been exploited as anticancer agents in clinical trials and basic
research for some time now. Nolte et al, 2018 report that 2-methylestradiol and its
sulfamoyl derivative induced mitochondrial apoptosis in radiation-exposed MCF-7 (model
for estrogen positive breast cancer) cells. Also, studies by Sara, 2018 documented that
estrone analogs with cucurbitacin pharmacophores inhibited the proliferation of
hepatocellular carcinoma via induction of apoptosis and suppression of EGFR and its
downstream MAP kinase signaling. In addition, estrone derivatives synthesized by our
research group, especially those bearing cucurbitacin side chains and that possessing nitric
oxide-releasing capabilities have been documented to exhibit potent cytotoxic effects
against distinct cancers (Ahmed et al, 2017; Elshaier et al, 2017; Ahmed et al, 2014; Kopel
et al, 2013; Abou-Salim et al, 2019). Also, Felix and colleagues (unpublished data)
revealed that these new estrone hybrids inhibited the proliferation of EGFR-wild-type
NSCLC (NCIH226 cells) via suppressing EGFR and MAP kinase signaling. Furthermore,
Verwey et al, 2016 reported that sulphamoylated estradiol derivative exhibited cytotoxic
effects through the induction of autophagy in MCF-7 and MDA-MB-231 cells. From all
the studies involving the use of estrone analogs, only Verwey and colleagues, 2016 have
tested estradiol analogs against MDA-MB-231 cells (a model for TNBC cells) for their
autophagic cell death effects. The current study sought to investigate the anticancer
potential of novel estrone hybrids against MDA-MB-468 cells. MDA‑MB‑468 cell line is
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a typical TNBC model that possesses stronger drug resistance and has higher rates of
recurrence and metastasis due to overexpression of EGFR. Currently, there is no targeted
agent approved for the treatment of TNBC. From this research, we showed for the first
time that most of our estrone hybrids were more potent that reference compound sorafenib.
Especially, MMA307 and MMA321 were over 10-fold and 20-fold, respectively potent
than the positive control sorafenib (Table 3.1).

Apoptosis mechanism is a complex process of programmed cell death that is regulated by
different cell signals. This mechanism is initiated and executed through two major
pathways, namely, the extrinsic and intrinsic pathways (Elmore, 2007). The extrinsic
pathway is triggered by extracellular ligands binding to cell surface death receptors. The
intrinsic pathway is initiated by a variety of intracellular factors generated when cells are
stressed. The BCL‑2 family of proteins play a key role in regulating the intrinsic pathway.
BCL‑2 protects the cell against apoptosis, but BAX and the BCL‑2 homologous killer,
BAK, induce cellular apoptosis through the mitochondria (Alberts et al, 2002). This
requires the release of cytochrome c which activates APAF1 through the formation of an
apoptosome. Both the intrinsic and extrinsic pathways have a final common pathway,
which involves activation of the effector caspases (caspase‑3/7) by initiator caspases
(caspase 8 for extrinsic pathway and caspase 9 for intrinsic pathway) (Dewangan et al,
2018). Finally, caspase 3 cleaves and inactivates PARP-poly (ADP-ribose) polymerasewhich is important for damaged DNA repair (Soldani and Scovassi, 2002). Therefore, the
expression of BCL‑2, cytochrome c, active caspase‑3 and 9, cleaved PARP become

123

important mitochondrial apoptosis indicators. In this research, we first analyzed PS flipping
which occurs during early apoptosis. Viable cells contain phosphatidylserine (PS), located
within the inner leaflet of the cell membrane. PS flips to the outer leaflet of the lipid bilayer
and becomes exposed on the cell surface during apoptosis. This allows for the binding of
annexin V dye. Analyzing MDA-MB-468 treated cells with real-time annexin V assay, it
was observed that MMA307 and MMA321 induced PS translocation within 12 hrs in a
dose-dependent fashion when compared to camptothecin, positive control (Figure 3.6A).
Subsequently, morphological changes, thus chromatin condensation, induced by the
estrone analogs were analyzed by fluorescence microscopy after staining cells with
Hoechst 33342. Chromatin condensation paralleled by DNA fragmentation is one of the
most important criteria which are used to identify apoptotic cells. Both MMA307 and
MMA321 as well as sorafenib, clearly induced chromatin condensation within 12 hrs of
drug treatment (Figure 3.6 B). Furthermore, we demonstrated that cytochrome c, APAF1,
active caspase‑3 and -9 expression levels were increased (Figures 3.7 and 3.8) but BCL‑2
expression levels were decreased (Figure 3.7) in MMA307 and MMA321 treated cells.
These findings suggest that these compounds induced mitochondrial or intrinsic apoptosis
in MDA‑MB‑468 cells.

Altered cell division is a hallmark of cancer. Targeting the cell cycle has proven to be a
key strategy in treating breast cancer, and several drugs targeting this pathway have been
approved by the FDA (Lo et al, 2017). The interaction among cyclins, cyclin-dependent
kinases (CDKs) and cyclin-dependent kinase inhibitors (CKIs) play a fundamental role in
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cell cycle progression (Uroz et al, 2018). Cyclin D and its specific CDKs are the crucial
regulators in the G1 phase of cell division. It has been documented that cyclin D is an
oncogene whose overexpression may be associated with poor prognosis in TNBC (Ly et
al, 2017). Cells will usually synthesize cyclin D in response to the mitogenic stimulation.
An increased amount of cyclin D interacts with CDK4/6 to phosphorylate the inhibitory
protein retinoblastoma (Rb) in the G1 phase, which leads to the dissociation of Rb from the
transcription factor E2F and promote E2F-dependent transcription. E2F activation could
promote a series of subsequent events that favor DNA replication and expression of cyclin
E and CDK2 (Bertoli et al, 2013) which transitions cells into the G2/M phase.
Phosphorylating cyclin D by cyclin-dependent kinase inhibitors, p21 and p27, leads to cell
cycle arrest within the G1 phase. In the present study, the expression levels of cyclin D1
were downregulated in MDA-MB-468 cells after MMA307 and MMA321 treatment
(Figure 3.9 B), suggesting that their significant G0/G1 phase cell cycle arrest (Figure 3.9 A)
was at least partially mediated via suppression of cyclin D1. It must be mentioned that
while the status of selected G1 phase cell cycle activator, cyclin D1, was analyzed in this
study, the functions of other G1 phase proteins were likely modulated as well, and therefore,
the antiproliferative effects of the estrone analogs reported here may not be solely due to
these proteins.

EGFR is a central regulator of cell proliferation through multiple downstream targets.
Dysregulation of EGFR signaling has been implicated in cancer. Phosphorylation of EGFR
on Y1068 creates docking sites for the adaptor protein, Grb2, leading to activation of the
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MAPK/ERK cascade, and a binding site for Gab1, which recruits the p85 subunit of
phosphatidylinositol 3-kinase (PI 3-kinase), leading to AKT activation (Yamaoka et al,
2011). EGFR is overexpressed and genetically amplified in one-third of metastatic or
recurrent breast cancers, and this has been inversely correlated with relapse-free survival
(Nagaria et al, 2017). The Ras/MAPK pathway is initiated through the promotion of Ras
binding to guanosine triphosphate (GTP), which in turn activates RAF kinases
MAPK/extracellular signal-regulated kinases (MEK), and ERK (Slomovitz and Coleman,
2012). Activated ERK is thought to translocate into the nucleus, where it phosphorylates
and activates transcription factors like elk-1, c-jun, fos, etc. that regulate the cell cycle. The
PI3K/Akt pathway is an important regulator of cell growth and survival through multiple
downstream targets and it has been shown that AKT could promote the activation of mTOR
through either mTORC1 or mTORC2 complex, which in turn, activates the p70S6 kinase
and promote cell growth (Manning and Toker, 2017). In the present study, MMA307 and
MMA321 decreased the expression of EGFR and activated EGFR (Y1068) (Figure 3.10).
Also, the expression levels of phosphorylated ARaf, phosphorylated ERK1/2,
phosphorylated AKT, phosphorylated mTOR and phosphorylated p70S6 kinase were
reduced upon MDA-MB-468 cells exposure to MMA307 and MMA321 (Figures 3.10 and
3.11). Our findings reveal that MMA307 and MMA321 might have inhibited TNBC cells
growth via impacting EGFR, Raf/MAPK, and Akt/mTOR signaling pathway.

3.6

Conclusion
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The present study gives preliminary convincing results on novel estrone analogs favorable
cytotoxic effects against TNBC in vitro. However, the mechanisms by which these novel
estrone analogs show anticancer effects and its direct target have never been exploited
before, which prompted further investigations. This study revealed that the estrone analogs
induced mitochondrial apoptosis, arrested G1 phase of the cell cycle, suppressed activated
EGFR and its downstream MAPK and AKT signaling. To the best of our knowledge, there
was no report about estrone analogs with modified cucurbitacin side chains having
potential applications in treating TNBC which possesses a high risk of brain metastasis.
Our work lays a foundation for using these new estrone analogs to treat TNBC, which
currently lacks any effective treatment options. Therefore, our results suggested that
MMA307 and MMA321 might be potential therapeutic agents for treating TNBC, which
deserves further investigation.
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Figure 3.1 Molecular docking study of designed estrone analogs against EGFR binding
site (Pdb: 1M17). Scatter plot of compounds consensus scores generated by VIDA
application.
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Figure 3.2 3D visual representation of reference drug, erlotinib, docked against EGFR
binding site. There is hydrogen bonding from the pyrimidine-N2 of erlotinib towards
MET769A of 1M17 binding site.
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Figure 3.3 3D visual representation of MMA307 docked against EGFR binding site (Pdb:
1M17). There is cation-π interactions between LYS721A of 1M17 and the steroidal
aromatic ring of MMA307.
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Figure 3.4 3D visual representation of MMA321 docked against EGFR binding site (Pdb:
1M17). The dashed green line shows hydrogen bonding from the Nitro-O of MMA321
towards THR830A of 1M17.
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Table 3.1 Cytotoxic effects of estrone analogs against the viability of MDA-MB-468 cells
in vitro.
IC50 Values (μM)
Compound

MDA-MB-468

MMA228

44.51 ± 2.06***

MMA271(R)

4.39 ± 0.07

MMA271(S)

4.06 ± 0.00

MMA287

2.51 ± 0.12**

MMA290

24.95 ± 0.05***

MMA292

> 50***

MMA294

5.48 ± 0.18

MMA295

2.98 ± 0.17**

MMA300

0.89 ± 0.10***

MMA305

27.00 ± 3.56***

MMA306

9.43 ± 0.07

MMA307

0.85 ± 0.00***

MMA308

34.68 ± 0.59***

MMA311

8.82 ± 0.08

MMA312

7.45 ± 0.09

MMA320

1.71 ± 0.01***

MMA321

0.56 ± 0.01***

MMA323

> 50

MMA327

49.81 ± 4.50***

MMA334

9.98 ± 0.30

Sorafenib

10.09 ± 0.68

Cytotoxic activities (IC50, μM) of estrone analogs against MDA-MB-468 cells in vitro. IC50
values were calculated by non-linear regression analysis. Values represent Mean ± SD of
quadruplicate experiment (n = 4). *** represent the significant differences in cytotoxic
effects of estrone analogs compared to sorafenib (positive control). *** p < 0.001 was
considered as statistically significant.
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Scheme 3.1 Synthesis route for MMA307.
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Scheme 3.2 Synthesis route for MMA321.
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Figure 3.5 Structures of MMA307 and MMA321. MMA307 was named as
(8S,9S,13S,14S,17S)-7,8,9,11,12,13,14,15,16,17-decahydro-17-((R,E)-2-hydroxy-5-(4nitrophenyl)-3-oxopent-4-en-2-yl)-13-methyl-6H-cyclopenta[a]phenanthren-3-yl
sulfamate
and
MMA321
named
as
4-Hydroxy-4-(3-methoxy-13-methyl7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl)-1-(4-nitrophenyl)-pent-1-en-3-one.
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Figure 3.6 Initial apoptosis induction and chromatin condensation observed in MDA-MB468 cells assayed by Annexin V and Hoechst staining, respectively. (A) Cells were treated
with 0.5IC50 and IC50 of MMA307, MMA321 or positive control, camptothecin for 12
hrs. The cells were then incubated with Annexin V reagent and luminescence measured by
a luminometer. At least two independent experiments were performed in triplicate. (B)
MDA-MB-468 cells were treated with 0.05% DMSO, IC50 doses of MMA307, MMA321
or positive control, sorafenib. Apoptotic cells exhibited chromatin condensation.
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Figure 3.7 Expression levels of cytosolic BCl2 and APAF1 in MDA-MB-468 cells assayed
by In-Cell Western (ICW). After treatment with MMA307 and MMA321 in a dosedependent manner, fixed cells were incubated with specific primary antibodies for each
protein. The cells were washed and incubated with goat anti-rabbit horseradish peroxidase
conjugated secondary antibodies, and cell mixture was incubated with enhanced
chemiluminescence substrate (Western Lightning Plus-ECL) for few minutes before
chemiluminescence was measured using a Hidex Sense Beta Plus plate reader (Turku,
Finland). Quantitation of proteins was completed with Excel and expression levels of
APAF1 and BCl2 normalized to GAPDH. At least two independent experiments were
performed. (A) BCl2 (B) APAF1.
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Figure 3.8 Expression levels of cytosolic BCl2 and APAF1 in MDA-MB-468 cells assayed
by In-Cell Western (ICW). After treatment with MMA307 and MMA321 in a dosedependent manner, fixed cells were incubated with specific primary antibodies for each
protein. The cells were washed and incubated with goat anti-rabbit horseradish peroxidase
conjugated secondary antibodies, and cell mixture was incubated with enhanced
chemiluminescence substrate (Western Lightning Plus-ECL) for few minutes before
chemiluminescence was measured using Hidex Sense Beta Plus plate reader (Turku,
Finland). Quantitation of proteins was completed with Excel and expression levels of
caspase 3, 9 and cytochrome C normalized to GAPDH. At least two independent
experiments were performed. (A) MMA307 (B) MMA321
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Figure 3.9 Estrone analogs exposure resulted in G1 phase cell cycle arrest. MDA-MB-468
cells were treated with IC50 concentrations of estrone analogs and analyzed after 48 hrs by
flow cytometry. (A) Distribution of cells in distinct phases of the cell cycle. MMA307,
MMA321 and sorafenib, positive control, showed G0/G1 phase cell cycle arrest compared
to the negative control, DMSO. (B) Cells were treated with indicated concentrations, fixed
and analyzed by ICW. Wells were incubated with appropriate primary antibodies and
subsequently incubated with Western Lightning Plus-ECL for few minutes before
chemiluminescence was measured using Hidex Sense Beta Plus plate reader (Turku,
Finland). The expression levels of cyclin D1 was normalized to GAPDH. The bar graphs
for cell cycle distribution show Mean ± SD of the percentages of MDA-MB-468 cells in
the indicated phases of the cell cycle (G0/G1, S and G2/ M). At least three independent
experiments were performed. ***p < 0.001 significant differences in cell cycle arrest
compared to DMSO control.
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Figure 3.10 Effect of estrone analogs treatment on EGFR and downstream ERK1/2
effector molecules in MDA-MB-468 cells. Cells were treated with varying IC50
concentrations for 6 hrs followed by 100 nM of EGF for 1 hr, fixed and analyzed by ICW.
Wells were incubated with appropriate primary antibodies, washed and incubated with goat
anti-rabbit or goat anti-mouse horseradish peroxidase conjugated secondary antibodies,
and cell mixture was incubated with enhanced chemiluminescence substrate (Western
Lightning Plus-ECL) for few minutes before chemiluminescence was measured using
Hidex Sense Beta Plus plate reader (Turku, Finland). Quantitation of proteins was
completed with Excel and expression levels of EGFR, pEGFR (Y1068), pARaf (S299) and
pERK1/2 (T202/Y204) normalized to GAPDH. At least two independent experiments were
performed. (A) MMA307 (B) MMA321.
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Figure 3.11 Effect of estrone analogs treatment on Akt signaling in MDA-MB-468 cells.
Cells were treated with varying IC50 concentrations for 6 hrs followed by 100 nM of EGF
for 1 hr, fixed and analyzed by ICW. Wells were incubated with appropriate primary
antibodies, washed and incubated with goat anti-rabbit or goat anti-mouse horseradish
peroxidase conjugated secondary antibodies, and cell mixture was incubated with
enhanced chemiluminescence substrate (Western Lightning Plus-ECL) for few minutes
before chemiluminescence was measured using Hidex Sense Beta Plus plate reader (Turku,
Finland). Quantitation of proteins was completed with Excel and expression levels of
EGFR, pEGFR (Y1068), pARaf (S299) and pERK1/2 (T202/Y204) normalized to
GAPDH. At least two independent experiments were performed. (A) MMA307 (B)
MMA321.
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Chapter 4

Exposure of Triple Negative Breast Cancer cells to Novel Triazole Derived Estrone
Analogs Enhance Mitochondrial Apoptosis Induction and EGFR Suppression.
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4.1

Abstract

Previously estrone analogs have been examined as effective clinical agents targeting
cancers including triple negative breast cancer (TNBC). However, no estrone analog nor
other agent is currently approved as targeted therapy for TNBC. In this study we describe
the synthesis and biological activity of novel triazole derived estrone analogs (Fz series)
targeting EGFR in MDA-MB-231 (a model for TNBC) cells in vitro; knowledge that will
pave a way for future clinical applications for these cytotoxic compounds. Molecular
docking studies were carried out with OpenEye software. The MTT assay was used to
perform cytotoxicity studies. Morphological changes and cell cycle arrest were carried out
by microscopy and flow cytometric techniques. Annexin V assay was used to evaluate
initial apoptosis induction in MDA-MB-231 cells and In-cell western assay was used to
detect the expression levels of apoptotic, cell cycle and EGFR and its downstream AKT
and ERK1/2 associated proteins. We demonstrated that Fz25 showed strong binding
affinity towards the EGFR kinase domain (pdb code: 1M17) in silico, like the reference
compound, erlotinib, but exhibited hydrogen bonding towards different amino acid
residues. Fz200 showed medium binding affinity whereas Fz57 showed weak binding
affinity. Fz25 was slightly cytotoxic than sorafenib when dosed to MDA-MB-231 cells;
Fz200 had similar IC50 value as sorafenib whereas the IC50 value of Fz57 was higher.
Moreover, condensed nuclei with fragmented chromatin, phosphatidylserine flip, and
changes in mitochondrial membrane potential clearly indicated the role of mitochondria in
estrone analogs induced apoptosis. Also, an increase in the expression of proteins of the
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intrinsic pathway (Apaf1, cytochrome c, cleaved PARP1, caspase-3, -9) confirms
mitochondrial apoptosis and suggest estrone analogs induced apoptosis via caspase
dependent pathways. Fz25 downregulated DyrK1B and cyclin D1 expression levels
contributing to G1 phase cell cycle arrest; Fz200 and Fz57 inhibited the expression of cyclin
E impacting S-phase of the cell cycle. All the compounds inhibited the expression of EGFR
and activated EGFR (Y1068); Activated proteins within ERK1/2 and AKT pathways were
downregulated upon compound treatment. These results for the first time indicate that
triazole derived estrone analogs may be an effective therapy for MDA-MB-231 cells and
further studies are needed to develop these novel candidates as targeted agents for TNBC.

Keywords: Estrone analogs; TNBC; EGFR; cytotoxic studies; Apoptosis; Cell cycle
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4.2

Introduction

Breast cancer continues to be the most common solid tumor affecting women and is the
leading cause of cancer-associated mortality in females worldwide (Bray et al, 2018). Also,
it is a heterogeneous disease with multiple subtypes including triple-negative breast cancer
(TNBC). TNBC, which is clinically defined by the absence of estrogen receptor (ER),
progesterone receptor (PR) and human epidermal growth factor receptor (HER2)
expressions, forms about 20% of all breast cancer cases (Guerrab et al, 2016). According
to molecular classification, about 75% of TNBC belong to the basal-like subtype and share
a great similarity with infiltrating carcinomas carrying constitutional BRCA1 mutations
(Santonja et al, 2018; Omarini et al, 2018). Its pattern of spread is distinct from that for
non-TNBC; TNBC has a greater propensity for brain and lung metastases, and a lower
prevalence of bone metastases (Lebert et al, 2018). Systemic chemotherapy including
anthracyclines, taxanes and platinum compounds remains the most effective treatment for
TNBC patients with advanced disease. Despite the effectiveness of these treatment
modalities, patients who do not respond to chemotherapy develop resistance, and a more
aggressive recurrent disease results which become virtually incurable (Székely et al, 2017;
Wahba and El-Hadaad, 2015). In contrast to other cancers, no targeted therapy is currently
approved for treating TNBC.
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Previous studies report that the epidermal growth factor receptor (EGFR), a central
regulator of tumor progression, is frequently overexpressed and aberrantly activated in
TNBC (Yan et al, 2018; Nakai et al, 2016). This is associated with aggressiveness and poor
prognosis of the disease. EGFR is a transmembrane tyrosine kinase receptor member of
the HER family. Autophosphorylation of the intracellular EGFR domain activates multiple
downstream signaling pathways including RAS/MAPK and PI3K/Akt cascades that lead
to transcriptional regulation of genes involved in cell proliferation, motility and survival.
As such, EGFR is considered a key clinical target for therapeutic intervention in TNBC.
PI3K/Akt pathway regulates diverse cellular functions such as cell cycle progression and
apoptosis whereas deregulation of its activity contributes to cell transformation (Ornelas et
al, 2013). Cell cycle progression is initiated by the activity of phase-specific kinase
complexes comprised of cyclins and cyclin-dependent kinases (CDKs) and the role of
PI3K/Akt pathway in G1 to S phase transition was proposed. Also, during cell cycle
progression, Akt prevents cyclin A, D and E degradation by regulating the activity of GSK3
and can negatively influence the expression of the CDK-inhibitors, p21 and p27 (Wang et
al, 2015; Ornelas et al, 2013). In addition to the cell cycle, apoptosis induction of cancer
cells is one of the most important and direct ways to contribute to the suppression of
malignant transformation and eliminate tumors. Phosphorylated Akt inhibits apoptosis and
promotes cell survival by phosphorylation and inactivation of several target proteins
including the proapoptotic proteins, Bad, Bax, and the tumor suppressor p53, a regulator
of Bcl-2 as well as initiator caspases-8 and -9 and effector caspase-3 (Hossini et al, 2016).
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In cancers like non-small cell lung cancer and colorectal cancer, anti-EGFR agents, small
molecule tyrosine kinase inhibitors and monoclonal antibodies, have been developed and
currently been used to treat these diseases. Monoclonal antibodies (mAbs) target the
extracellular domain whereas EGFR tyrosine kinase inhibitors (EGFR-TKIs)
competitively block the binding of adenosine 5′ triphosphate (ATP) to the intracellular
catalytic domain of EGFR. In both cases, mAbs and EGFR-TKIs are able to inhibit EGFR
activation and thus suppress its downstream signal transduction (Imai, 2006). Cetuximab
and panitumumab are two mAbs that are approved for the treatment of EGFR-expressing
metastatic colorectal cancer with KRAS wild-type. Osimertinib, gefitinib, afatinib and
erlotinib are few selective EGFR-TKIs used as therapy for patients with metastatic nonsmall-cell lung cancer who carry activating EGFR mutations (Rosa et al, 2015; Nakai et
al, 2016; Bartholomew et al, 2017). Several clinical trials report the use of already
discovered anti-EGFR inhibitors, either alone or in combination with chemotherapy or
other therapies, as a treatment option for TNBC patients. In phase II clinical trial, gefitinib
and erlotinib used as monotherapies in metastatic and recurrent breast cancer patients
yielded only a partial response of 0-3% (Baselga et al, 2005; Dickler et al, 2009). Also, in
another phase II clinical trial with second-generation irreversible EGFR TKI, afatinib, in
patients with metastatic TNBC, no objective responses were observed (Nakai et al, 2016).
In a different phase II clinical studies, the combination of cetuximab plus carboplatin
showed an improved response rate than cetuximab or carboplatin alone (Carey et al, 2012).
In light of this, only minimal success has been achieved and therefore the need to discover
newer effective anti-EGFR agents is imperative.
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Currently, natural endogenous metabolites of mammalian origin have become an alternate
source for the discovery of anticancer agents for therapeutic intervention. In this regard,
estradiol analogs have turned out to be the focus of research due to their ability to exert
significant antimitotic effects against various cancers including breast cancer. In particular,
Stander et al, 2011 report that 2-Methoxyestradiol (2ME), an endogenous metabolite of
17β-estradiol, possess both antiangiogenic and anti-breast cancer effects in vitro and in
vivo. This compound exerts its cytotoxic effect independently of the cellular estrogen
receptors and has no significant systemic hormonal effects (Leese et al, 2006). Estradiol,
however, promotes the proliferation of various cancers (Verwey et al, 2016). The above
studies also report on the limited bioavailability of the 2ME (Panzem®) drug due to its
fast-metabolic breakdown during phase II clinical studies. Recently, a sulfamate derivative
of 2ME has been found to possess potent antitumor activity against breast cancer cells due
to its increased bioavailability by avoiding hepatic first-pass metabolism (Visagie et al,
2013; Verwey et al, 2016). This suggests that estradiol may be a privileged scaffold upon
which modifications can be done to generate lead candidates with improved potency and
pharmacokinetic properties as well as reduced toxicities. In our research group, estrone, an
isomer of estradiol, is used as a starting material to synthesize novel estrone analogs. Many
of our estrone derivatives, especially those bearing cucurbitacin side chains have been
documented to exhibit potent cytotoxic effects against distinct cancers (Ahmed et al, 2017;
Elshaier et al, 2017; Ahmed et al, 2014; Kopel et al, 2013). On the other hand, a set of
novel compounds carrying 1,2,3-triazole scaffold has been reported as cytotoxic agents
against different cancers (Prachayasittikul et al, 2015; El-Sherief et al, 2018). Recently,
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our research group has synthesized a new series of estrone analogs (bearing modified
triazole side chains) targeting EGFR dependent cancers using pharmacophore-dockingbased virtual screening. In this study, we report on the synthesis and biological evaluation
of novel estrone analogs bearing triazole side chains as potent compounds against EGFR
dependent breast cancer cells. These compounds inhibited the MAP kinase and Akt
signaling as a result of deregulating EGFR expression and induced apoptosis.

4.3

4.3.1

Materials and methods

Reagents and chemicals

Antibodies against EGF Receptor (D38B1) XP®, Phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) (197G2), Cyclin D1 (92G2), Phospho-Akt (Ser473) and anti-rabbit
DyLight 680 conjugate (5366) secondary antibody were purchased from Cell Signaling
Technology (Danvers, MA, USA); phospho-cyclin D1 (Thr286) (A537487), Phospho-ARaf (Ser299) and anti-mouse DyLight 800 conjugate (W10815) from Thermo Fisher
Scientific (Waltham, MA, USA); Phospho-EGF Receptor (Tyr1068), Phospho-p70S6
Kinase α, Dyrk1B, caspase 9, caspase 3, PARP1, cleaved PARP1, Bcl-2, APAF1,
cytochrome C, Cyclin E and GAPDH were from Santa Cruz Biotechnology Inc. (Dallas,
Texas, USA). Phosphate buffered saline (PBS) and trypan blue solution were from Thermo
Fisher Scientific (Waltham, MA, USA). RealTime-Glo™ Annexin V apoptosis and
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necrosis assay (JA1011) kit was from Promega (Madison, WI, USA). PI/RNase staining
buffer was purchased from BD Biosciences (San Jose, CA, USA). Compound cytotoxicity
was evaluated through measurement of mitochondrial dehydrogenase activities with 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (SigmaAldrich, St. Louis, MO, USA). Hoechst 33342 stain for evaluating chromatin condensation
and nuclear fragmentation was purchase from Thermo Fisher Scientific (Waltham, MA,
USA). Sorafenib (positive control) (Selleckchem, Houston, TX, USA) and novel triazole
derived estrone analogs were dissolved in dimethyl sulfoxide (DMSO) (Fisher
Chemical/Fisher Scientific). All other chemicals were of analytical grade.

4.3.2

Design and synthesis of estrone analogs

4.3.2.1 Molecular modeling

Molecular docking of novel estrone analogs into the EGFR binding domain (PDB code:
1M17) was carried out using the FRED application (version 2.2.5) as implemented through
the graphical user interface of OpenEye® software. The 3D structure of the above protein
was downloaded from Protein Data Bank. The three-dimensional structures of the
aforementioned compounds were constructed using Chem. 3D ultra 12.0 software
[Chemical Structure Drawing Standard; Cambridge Soft corporation, USA (2010)], then
they were energetically minimized by using MMFF94 with 5000 iterations and minimum
RMS gradient of 0.10. All bound water molecules and ligands were eliminated from the

158

proteins. Furthermore, multi-conformers were generated using OMEGA application
(version 2.5.1.4) and VIDA application (version 4.1.2) was used as a visualization tool to
show the potential binding affinity and binding interactions of the ligands to the receptor
[24]. This software package generates consensus scoring which is a filtering process to
obtain virtual binding affinity. The lower the consensus score, the better binding affinity
of the ligands towards the receptor.

4.3.2.2 Synthesis of MMA307 and MMA320

Fz25, Fz57, and Fz200 were synthesized as previously described by Faez, 2017.

4.3.3

Cell culture

MCF-7 (a model for ER+, PR+, HER2- breast cancer) and MDA-MB-231 (a model for
TNBC with amplified EGFR and KRAS mutant) were purchased from American Type
Culture Collection (ATCC, Manassas, VA). The cells were cultured in Dulbecco's
Modified Eagle Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS),
antibiotic-antimycotic (Gibco™, ThermoFisher Scientific) at 37˚C equilibrated with 5%
(v/v) CO2 in humidified air. The cells for the assays were detached using a solution of
trypsin with EDTA (ThermoFisher Scientific).
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4.3.4

Cytotoxicity assay

4.3.4.1 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Assay

The effect of novel synthetic estrone analogs on cell viability was tested with MTT reagent
as described by Wang et al, 2010 with slight modifications. Briefly, to measure
mitochondrial dehydrogenase activities, cells were seeded in 96-well plates at an initial
density of 30,000 cells per well. After overnight incubation, cells were treated with
different concentrations of compounds in a dose range of 0 - 100 μM. The final DMSO
concentration was 0.05%. After 48 hrs of incubation, 20 μL of MTT reagent (5 mg/mL)
was added to each well and the formed formazan crystals were dissolved in 250 μL of
dimethyl sulfoxide (DMSO). Four independent experiments were completed to determine
the mean optical density referred to as cell viability, using a Hidex Sense Beta Plus plate
reader (Turku, Finland). Cell viability was expressed as a percentage of DMSO-treated
controls.

4.3.5

Flow cytometry for cell cycle analysis

MDA-MB-231 and MCF-7 cells were seeded into six-well plates at a concentration of
300,000 cells/ well and allowed to attach in culture overnight, then treated with IC50 of
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compounds or positive control (sorafenib) for 48 h. Afterward, cells were washed with PBS
and harvested. Cell cycle analysis was investigated by adding propidium iodide (PI) stain
(Thermo Fisher Scientific) to 1 mL of cell suspension. Briefly, harvested cells were fixed
in 70% ethanol and incubated at 4ºC for 4hrs. Subsequently, the cells were cleaned of
alcohol and stained with RNase free PI solution, the cell suspension was incubated in the
dark for 45 minutes at room temperature. The samples were analyzed by flow cytometry
and compared to DMSO-treated cells. All these experiments were performed on BD
Accuri™ C6 flow cytometer (BD Biosciences, San Jose, CA, USA) using BD Accuri™
C6 software, version 1.0.

4.3.6

Apoptosis analysis

4.3.6.1 Annexin V assay

The annexin v assay was performed in accordance with the manufacturers’ protocol with
slight modifications. Briefly, MDA-MB-231 and MCF-7 cells were seeded in wells on a
96-white plate with clear bottom at an initial density of 30,000 cells for overnight
attachment. Afterward, the cells were incubated with the IC50 of compounds between 6 to
48 hrs. Subsequently, the RealTime-Glo™ Annexin V Apoptosis reagent (Promega,
Madison, WI) was prepared (sequentially mix Annexin NanoBiT® Substrate, CaCl 2,
Annexin V-SmBiT and Annexin V-LgBiT in a prewarmed media) and added to the reaction
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set up before incubating for additional 1 hr. Luminescence was measured afterward using
Hidex Sense Beta Plus plate reader (Turku, Finland). Apoptosis was expressed as a
percentage relative to DMSO-treated controls.

4.3.6.2 Morphological analysis with fluorescence microscopy

To evaluate the apoptotic activity of the estrone analogs, nuclear staining with the DNAbinding dye Hoechst-33342 performed in accordance with manufacturers protocol. In brief,
MDA-MB-231 and MCF-7 cells were plated into 6-well plates and treated with IC50 of
compounds for 24 hrs. Cells were washed with PBS and incubated with Hoechst-33342
(10μg/mL) for 15 min in the dark, then observed under a fluorescence microscope
(excitation 352 nm, emission 461 nm; NIKON TE2000-E). Apoptotic cells were identified
by condensation of chromatin and fragmentation of nuclei. Pictures were obtained using a
video camera Q-imaging (Burnaby, BC, Canada).

4.3.7

Protein expression analysis

4.3.7.1 In-Cell Western (ICW) Assay

Proteins involved in apoptosis, cell cycle progression, MAP kinase and Akt pathways were
quantified by ICW. This technique was carried out in accordance with the manufacturer’s
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instruction with slight modifications. Briefly, about 50,000 cells per well were seeded into
96-well black walled plate with clear bottom for overnight attachment. Cells were then
treated with IC50 of compounds for 24 hrs. Subsequently, cells were fixed with 3.7%
formaldehyde solution, permeabilized with 0.1% Triton X-100 solution and blocked with
fish gel buffer (1×) prior to primary antibody addition. Wells were then incubated with the
relevant antibodies EGF Receptor (D38B1) XP®, Phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204) (197G2), Cyclin D1 (92G2), Phospho-Akt (Ser473), phospho-cyclin D1
(Thr286) (A537487), Phospho-A-Raf (Ser299), Phospho-EGF Receptor (Tyr1068),
Phospho-p70S6 Kinase α, Dyrk1B, caspase 9, caspase 3, PARP1, cleaved PARP1, Bcl-2,
APAF1, cytochrome C, Cyclin E and GAPDH, control, overnight followed by an hour
incubation with anti-mouse or anti-rabbit DyLight conjugated (680 or 800 nm) secondary
antibodies. Images were acquired using LICOR Odyssey® Fc Imaging System (Lincoln,
Nebraska, United States) and image quantification done by Fiji software (Image J, Java
1.8.0).

4.3.8

Statistical Analysis

Microsoft® Excel® for Windows, version 16.0., was used for the calculation of mean and
standard deviation values of different experiments and plotting of bar or line graphs. Mean
IC50 values were compared by one-way analysis of variance (ANOVA) using GraphPad
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Prism 5.01 (San Diego, USA) and values with p<0.05 were considered statistically
significant.

4.4

4.4.1

Results

Docking simulations

To validate whether these designed estrone analogs can target EGFR dependent breast
cancers, molecular docking was performed by fitting these designed compounds and
reference compound (erlotinib) into the ATP binding site of the EGFR kinase domain (PDB
codes: 1M17) crystallized from breast cancer cells. Then, the obtained results plotted as a
line-scatter graph (Figure 4.1), which mainly displays the corresponding consensus scores
of the molecular docking studies. Compared with the positive control drug, erlotinib, it was
clearly observed that most estrone analogs showed lower consensus scores (a measure of
better binding and potency) against EGFR kinase domain. Furthermore, Figure 4.3 – 4.5
show the binding mode of Fz25, Fz57 and Fz200 that exhibited potent cytotoxic activities
compared to sorafenib and estrone in vitro. Directed addition of trimethylsilyl azide to
compound 5 afforded Fz25 in 51% yield after column chromatography and the addition of
phenylacetamide substituted triazole to compounds 4 and 5 yielded Fz200 (73%) and Fz57
(69%), respectively, after silica-gel column chromatography purification. These pure
compounds were characterized by 1H- and

13

C-NMR and mass spectrometry techniques.
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The chemical shifts and accurate masses are documented in the method section. Fz25 was
named as 3-Obenzyl Estra-17 (-1H-1,2,3-triazol), Fz57 as 3-Obenzyl Estra-17 (1H-1,2,3triazol-1-yl)-N-phenylacetamide and Fz200 as 3-Oacetate estra-17 (1H-1,2,3-triazol-1-yl)N-phenylacetamide.

4.4.2

Estrone analogs exhibit cytotoxic effects and affect the morphology of breast
cancer cells

To evaluate the cytotoxic effects of the estrone analogs against MDA-MB-231 and MCF7 cells, the cells were initially treated with different concentrations of the compounds, a
dose range of 0-50 μM. Subsequently, effects on cell viability were determined by the MTT
assay after 48 hrs. Overall, the compounds did show a significant cytotoxic effect toward
the MDA-MB-231 and MCF-7 cells within the dose range tested after 48 h and therefore
IC50 values were calculated. Most of the compounds were equally effective as the positive
control-sorafenib but very potent than estrone in reducing the viability of MDA-MB-231
and MCF-7 cells. Particularly, we observed that Fz25, Fz57, Fz200, Fz300 and Fz400
recorded IC50 values of 8.12 ± 0.85, 21.18 ± 0.23, 10.86 ± 0.69, 14.95 ± 1.85 and 21.21 ±
0.76 μM, respectively (Table 4.1) against MDA-MB-231 cells. Also, Fz25, Fz57, Fz200,
Fz300 and Fz400 recorded IC50 values of 8.13 ± 0.15, 11.94 ± 0.19, 20.86 ± 3.16, 18.38 ±
1.97 and 21.49 ± 0.95 μM, respectively towards the MCF-7 cells. Fz25 recorded which
similar IC50 values in both cell lines was slightly better than the positive control, sorafenibrecorded an IC50 values of 10.62 ± 0.02 μM in MDA-MB-231 cells and 12.21 ± 0.96 μM
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in MCF-7 cells. Because this research was focused on EGFR dependent breast cancer,
further studies were conducted using the MDA-MB-231 cells. Morphological changes in
MDA-MB-231 cells induced by Fz25, Fz57, Fz200 and sorafenib (positive control) were
observed in Figure 4.6. Light microscope was used to evaluate the morphological response
when the cells were treated with IC50 doses of compounds for 48 h. The cells exposed to
0.05% of DMSO showed no signs of cell stress and confluent cell growth was seen.
Compared with DMSO control cells, the majority of the compound-treated MDA-MB-231
cells were stressed, and the confluency of the cells reduced. Particularly, the cells changed
from regular spindle-shape to an increased proportion of either round-shaped (observed for
Fz57) or rod-shaped (observed for Fz25, Fz200 and sorafenib) adding to the compound’s
cytotoxic effects.

4.4.3

Increased G1- or S-phase cell cycle arrest in response to estrone analogs
exposure

The quantification of cells at various stages within the cell cycle was determined with
propidium iodide stain and analyzed by flow cytometry. Cell cycle distribution of MDAMB-231 cells exposed to DMSO (Figure 4.11) showed an average of 40% in the G0/G1
phase, 2% in the S phase and 53% in the G2/M phase. The exposure of cells to Fz25 resulted
in significant accumulation of cells within G0/G1 phase, an average of 63%; there was
decreased enrichment of cells in the G2/M phase, an average of 29% was calculated. Fz57
and Fz200 treatments against MDA-MB-231 cells resulted in significant enrichment of
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cells within the S-phase of the cell cycle. Fz57 recorded an average of 47% of cells in the
S-phase and a lower number of cells (an average of 13%) in the G2/M phase. Similarly,
Fz200 recorded an average of 36% of cells within the S-phase and concomitant lesser
number of cells in the G2/M phase (an average of 22%).

4.4.3.1 Cell cycle activators and regulators are modulated post estrone analogs
exposure

As a result of the significant (p < 0.05) cell cycle arrest induced by the estrone analogs, we
analyzed the expression levels of known G1- and S-phase cell cycle proteins. In-Cell
Western approach was adopted to establish our findings. Cyclin D1 and Dyrk1B play
important roles in regulating the progression of the cell cycle within the G1 phase whereas
cyclin E is associated with controlling the S-phase of the cell cycle. We observed that Fz25
administration to MDA-MB-231 cells resulted in the suppression of cyclin D1 and Dyrk1B
in a concentration-dependent manner with 24hrs (Fig 4.12A). On the other hand, exposure
of Fz57 and Fz200 to the TNBC cell model resulted in downregulation of cyclin E in a
dose-dependent fashion (Fig 4.12B-C). These findings are in line with the significant cell
cycle arrest recorded in Figure 7.

4.4.4

Estrone analogs induce apoptosis in breast cancer cells
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4.4.4.1 RealTime-Glo™ Annexin V assay

The cell death inducing effect of the estrone analogs in MDA-MB-231 cells were evaluated
by RealTime-Glo™ Annexin V apoptosis and necrosis luminescent assay. The detection
reagent contains Annexin V-LgBiT and Annexin V-SmBiT (NanoBiT) fusion proteins and
a profluorescent DNA dye. In healthy cells, most of the phosphatidylserine (PS) is confined
to the inner leaflets of the cell membrane, fewer fusion proteins bind to PS and less
luminescence is recorded. In apoptotic cells, PS is exposed to the outer leaflet of the cell
membrane, more fusion proteins bind to PS and increased luminescence is measured.
Increased luminescence corresponds to increased apoptosis. Treating MDA-MB-231 cells
with the estrone analogs, increased apoptosis was observed in a dose-dependent manner
(Figure 4.7). Notably, Fz25 and Fz57 induced apoptosis in MDA-MB-231 cells within 6
hrs (Fig 4.7A) whereas the apoptotic effect recorded by Fz200 was observed within 48 hrs
of treatment (Figure 4.7B), all compared the positive control, camptothecin.

4.4.4.2 Morphological analysis with fluorescence microscopy

The morphological observation in the cell nuclei of MDA-MB-231 cells for 24 h after
treatment with estrone analogs or sorafenib showed significant morphological alterations
when compared to 0.05% DMSO control. As shown in Figure 4, the control or untreated
cells appeared to be intact oval shape and the nuclei were stained with a less bright blue
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fluorescence (due to the Hoechst 33342 dye). Cells treated with tested compounds
exhibited typical features of apoptosis such as cell shrinkage, chromatin condensation, and
fragmentation in multiple, segregated bodies, the formation of apoptotic bodies, and cell
decrement. The apoptotic nuclei clearly showed highly condensed or fragmented
chromatin that was uniformLy fluorescent. Fz25, Fz57, Fz200 and sorafenib treatments
resulted in increased apoptotic cells (condensed chromatin, indicated by arrows) compared
to the DMSO control (Figure 4.8).

4.4.4.3 Estrone analogs induce cell death via mitochondrial apoptosis pathway

In order to determine whether the compounds modulated proteins involved in cell death,
ICW assay was performed to detect changes of protein expression in the mitochondrial
apoptosis pathway. As shown in Figure 4.9, exposure of MDA-MB-231 cells to compounds
resulted in increased expressions of cytochrome C and apoptotic protease activating factor
1 (APAF1), which are markers of mitochondrial apoptosis. Furthermore, we observed
decreased expression of B Cell Lymphoma 2 (Bcl-2) protein when MDA-MB-231 cells
were treated with Fz57 and Fz200 (Figure 4.10 B-C) but not Fz25 (data not shown). Also,
all three compounds when administered to cells resulted in an increased expression of
cleaved PARP1 but had no effect on PARP1 in a dose-dependent fashion. However, the
expression levels of caspases-3 and -9 were decreased post-treatment with Fz57 and Fz200.
No change in the expression levels of caspases-3 and -9 were noted when MDA-MB-231
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cells were exposed to Fz25. In summary, these results reveal that the estrone analogs
induced apoptosis in MDA-MB-231 cells via the mitochondrial pathway and in a caspasedependent manner.

4.4.5

EGFR signaling pathways are inhibited after estrone analogs exposure

We evaluated the expression levels of total and activated (phosphorylated) forms of EGFR
by ICW (Figure 4.13). Higher levels of EGFR were detected in the DMSO treated cells
compared to compound treated cells, depicting EGFR downregulation. Similarly, levels of
phosphorylated EGFR (Y1068) were also increased in the DMSO treated cells compared
to compound-treated cells. EGFR and phosphorylated EGFR (Y1068) expression levels
were downregulated in a concentration-dependent manner. The purpose of EGFR
autophosphorylation is to activate signaling pathways, such as PI3K/AKT and
RAS/MAPK pathways (Romano et al, 2011). We next investigated the activation of these
pathways by quantifying activated (phosphorylated) forms of ERK1/2- and AKTassociated pathway proteins. Decreased amounts of phospho-ARaf (S299) and phosphoERK1/2 (T202/Y204) were clearly detected in MDA-MB-231 cells when exposed to the
estrone analogs in a dose-dependent manner (Figure 4.13). Also, phospho-AKT (S473),
phospho-mTOR (S2448) and phospho-p70S6Kα (S411) expression levels were
downregulated in concentration-dependent manner (Figure 4.14). Based on the levels of
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ERK- and AKT-associated proteins phosphorylation, RAS/MAPK and PI3K/AKT
signaling pathways were downregulated in MDA-MB-231 cell line.

4.5

Discussion

Estrone derivates, especially 2ME and its sulphamoylated analogs, have been proven to be
cytotoxic against various cancers including TNBC (Verwey et al, 2016, Nolte et al, 2018).
Mechanistically, the observed cytotoxicity has been attributed to inhibition of
angiogenesis, actin depolymerization, autophagy induction, and the modulation of both
intrinsic and extrinsic apoptosis. However, only a few studies have investigated estrone
analogs inhibitory effects against EGFR and its downstream signaling pathways. EGFR is
known to be overexpressed in TNBC. Previously, our research group has reported on
estrone analogs EGFR inhibitory effects in different cancers in vitro. Notably, studies by
Sara, 2018 documented that estrone analogs with cucurbitacin pharmacophores inhibit the
proliferation of hepatocellular carcinoma via induction of apoptosis and suppression of
EGFR and its downstream MAP kinase signaling. Also, Felix and colleagues (unpublished
data) revealed that these compounds inhibit the proliferation of EGFR-wild-type NSCLC
(NCIH226 cells) via inhibiting EGFR and MAP kinase signaling. Currently, we have
synthesized a new series of estrone analogs (bearing triazole or substituted triazole at
position 17 of the estrone scaffold-Fz series) using pharmacophore-docking-based virtual
screening. In this study, we report for the first time that the triazole substituted estrone
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analogs are potent cytotoxic agents against the MDA-MB-231 cell line. Also, these class
of compounds mechanistically elicited mitochondrial apoptosis induction and suppressed
EGFR expression as well as downregulate Akt and ERK1/2 pathways.

Previous co-crystallization studies by Stamos et al, 2002 revealed that hydrogen bonding
between the amide nitrogen of MET769A within the EGFR kinase domain (1M17) and the
pyrimidine N2 of erlotinib (reference compound) was a key molecular interaction achieving
drug potency (Figure 4.2). From our virtual screening studies in silico, we observed that
most of our estrone analogs had a similar or lower consensus score (a measure of drug
potency) compared to the reference compound, erlotinib (Figure 4.1). The lower the
consensus score, the stronger the binding and the better the compound’s potency. Fz25 and
Fz200 had similar consensus score compared to erlotinib whereas Fz57 had a higher
consensus score. These compounds showed interesting cytotoxic effects against MDAMB-231 cells in vitro. In contrast to the findings published by Stamos et al, 2002, we report
for the first time that Fz25, Fz57 and Fz200 showed hydrogen bonding towards different
amino acid residues within EGFR kinase domain (Figure 4.3 and 4.5). Fz25 displayed
hydrogen bonding from N1, N2 and N3 of the triazole ring and hydroxy group towards
ASP831A, GLU738A and THR766A amino acid residues, respectively, within the EGFR
kinase domain. Also, Fz200 showed hydrogen bonding from N2 and N3 of the triazole ring
towards the amide nitrogen of CYS773A. Similarly, Fz57 showed a single hydrogen
bonding from N3 of triazole towards the amide nitrogen of CYS773A. These different
interactions may be key to these compounds eliciting their cytotoxic effects against MDA-
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MB-231 cells. Next, the triazole substituent was installed onto the estrone scaffolded at
position 17 to produce Fz25 whereas the addition of phenylacetamide substituted triazole
onto the estrone nucleus afforded Fz200 and Fz 57 (Faez, 2017).

In the past our lab has designed several estrone analogs with enhanced cytotoxicity. These
and other estrone analogs (Stander et al, 2012) have demonstrated cytotoxicity within
nanomolar or micromolar concentrations against multiple cancer cell lines, including
MDA-MB-231 cells. The cytotoxic effect of Fz25, Fz57 and Fz200 was confirmed in the
current study revealing IC50 concentrations of 8.12 ± 0.85, 21.18 ± 0.23, 10.86 ± 0.69 μM,
respectively, compared to sorafenib, IC50 value of 10.62 ± 0.02 μM (Table 4.1). All except
Fz25 showed a different trend of cytotoxicity when MCF-7 cells were exposed to the
estrone analogs. However, MDA-MB-231 cells were considered for further investigations
because our hypothesis sought to test the estrone analogs cytotoxic effect against EGFR
dependent breast cancers. MCF-7 is a model for estrogen receptor (ER) positive breast
cancer and therefore does not fit into our hypothesis.

Cell cycle analysis suggested that the compounds inhibit cell growth via blocking cell
division at the G0/G1 and S phases. In addition, treatment of MDA-MB-231 cells resulted
in increased apoptosis (Figure 4.11). These results are in good agreement with previous
findings demonstrating that different estrone analogs also induced a G0/G1 cell cycle arrest
and apoptosis in human cancer cell lines in vitro (Verwey et al, 2016, Nolte et al, 2018;
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Wolmarans et al, 2014; Boyd et al, 2018). To better understand the mechanism of triazole
derived estrone analogs-induced cell cycle arrest and apoptosis, we firstly investigated the
status of key proteins known to regulate G0/G1 and S phases transition and cell death.
Dyrk1B, a checkpoint kinase important for G1 to S phase cell cycle transition is aberrantly
activated in many cancers, including breast cancer. In addition, Dyrk1B is responsible for
modulating the expression of several cell cycle activators (eg. Cyclin D1) and regulators
(eg. p27) (Chen et al, 2017). Our previous studies suggest that estrone analogs with
modified cucurbitacin pharmacophores induce inhibitory effects against human EGFRwild-type NSCLC cell lines via suppression of Dyrk1B expression (Unpublished Data). In
the current study, it was clearly demonstrated that the levels of Dyrk1B and cyclin D1
proteins were decreased in MDA-MB-231 cells treated with Fz25 (Figure 4.12), suggesting
that G0/G1 cell cycle arrest was at least partially mediated via suppression of cyclin D1 and
Dyrk1B expressions. Similarly, the levels of cyclin E were decreased when TNBC cells
were treated with Fz57 and Fz200 depicting that the S-phase cell cycle arrest was partially
mediated by downregulating cyclin E expression.

The apoptotic nature of cell death in triazole-derived estrone analogs-treated cells was
verified by different assays, including annexin V, chromatin condensation, and some
markers involved in the mitochondrial apoptosis cascade. Viable cells contain
phosphatidylserine (PS), located on the inside of the cell membrane. When apoptosis
occurs, PS flip will occur. PS moves to the outside surface of cells to which annexin V
binds. Analyzing MDA-MB-231 treated cells with real-time annexin V assay, it was
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observed that Fz25 and Fz57 induced PS translocation within 6 hrs whereas Fz200
exhibited PS translocation after 48 hrs in a dose-dependent fashion when compared to
camptothecin, positive control (Figure 4.7). Subsequently, morphological changeschromatin condensation, induced by the estrone analogs were analyzed by fluorescence
microscopy after staining cells with Hoechst 33342. Chromatin condensation paralleled by
DNA fragmentation is one of the most important criteria used to identify apoptotic cells.
All estrone analogs (Fz25, Fz57 and Fz200) and sorafenib, clearly induced chromatin
condensation within 24 hrs of drug treatment (Figure 4.8). These results are in line with
studies by (Verwey et al, 2016, Nolte et al, 2018) where different estrone analogs induced
PS translocation and chromatin condensation in the estrogen negative and metastatic breast
cancer cells, MDA-MB-231. Furthermore, the estrone analogs effect on markers involved
in the mitochondrial apoptosis were investigated. The Bcl-2, an antiapoptotic protein,
family consists of proapoptotic and antiapoptotic proteins. Bcl-2 binds to various
proapoptotic family members and inhibits their insertion into the mitochondrial membrane.
Upon receiving an apoptotic signal, Bcl-2 releases proapoptotic proteins, allowing them to
form a complex on the mitochondrial membrane. Cytochrome c is consequently released
into the cytoplasm, triggering increased caspase activity which leads to cell death. In
apoptotic cells, cytochrome c binds to Apaf-1 to induce apoptosome formation. The Apaf1 apoptosome catalyzes the autocatalytic activation of the caspase-9 zymogen (initiator
caspase), which subsequently cleaves and activates caspase 3 (Hu et al, 2014). Finally,
caspase 3 cleaves and inactivates PARP-poly (ADP-ribose) polymerase, which is
important for damaged DNA repair (Soldani and Scovassi, 2002). Estrone analogs
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administration to MDA-MB-231 cells resulted in mitochondrial apoptosis induction where
increased expressions of cytochrome c and Apaf-1 were observed whereas the expression
of Bcl-2 was decreased (Figure 4.9 and 4.10). Also, dosing Fz25 to MDA-MB-231 cells
resulted in stable expression of PARP 1 whereas the expression levels of caspase 9, caspase
3 and cleaved PARP 1 were increased. However, the levels of caspases-3 and -9 decreased
upon Fz57 and Fz200 treatment, but the levels of cleaved PARP1 increased (Figure 4.10).
These findings partially concur with studies by Nolte et al, 2018 where different estrone
analogs addition to MCF-7 cells decreased the expression of Bcl-2. This study is the first
to report on triazole derived estrone analogs mitochondrial-induced apoptosis in a TNBC
model.

Furthermore, we demonstrated that triazole derived estrone analogs can target directly the
epidermal growth factor receptor (EGFR), suppressing its phosphorylation at the docking
site Y1068 in a concentration-dependent manner in EGFR-expressing MDA-MB-231 cells,
followed by inhibition of its secondary PI3K/AKT and RAS/ERK signaling pathways.
Phosphorylation of EGFR on Y1068 creates binding sites for the adaptor protein, Grb2,
leading to activation of the MAPK/ERK cascade, and a binding site for Gab1, which
recruits the p85 subunit of phosphatidylinositol 3-kinase (PI 3-kinase), leading to AKT
activation (Yamaoka et al, 2011). EGFR is overexpressed and genetically amplified in onethird of metastatic or recurrent breast cancers, and this has been inversely correlated with
relapse-free survival (Nagaria et al, 2017). EGFR has been implicated in numerous
processes including promoting tumor cell development and proliferation, and survival by
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activating the MAPK/ERK and AKT pathways, respectively (Nagaria et al, 2017).
MAPK/ERK activation leads to the induction of target proteins, including Bcl-2, caspase9, and cyclin D1, regulating growth and proliferation of cells (Nagaria et al, 2017).
Similarly, activated AKT exerts its survival and protein synthesis activities by directly
activating mammalian target of rapamycin (mTOR) and ribosomal protein S6 kinase
(p70S6K) (Manning and Toker, 2017). Therefore, considerable attention has been given to
targeting the EGFR pathway for anticancer therapy. It must be noted that currently no antiEGFR agent has been approved for treating TNBC clinically. Treating MDA-MB-231 cells
with estrone analogs resulted in decreased expression of EGFR in a dose dependent manner
within 24 hrs. Similarly, activated EGFR (Y1068) expression levels were downregulated
after estrone analogs administration (Figure 4.13). Furthermore, MAPK/ERK pathway was
inactivated as the compounds downregulated the expression levels of phospho-ARaf
(Ser299) and phospho-ERK1/2 (T202/Y204) (Figure 4.13) in a dose-dependent fashion.
The AKT pathway was also inactivated as the expression levels of activated proteins,
phospho-AKT (Ser473), phospho-mTOR (Ser2448) and phospho-p70S6Kα (Ser411)
(Figure 4.14) were decreased when the TNBC model was treated with triazole derived
estrone analogs.

It must be mentioned that while the status of selected cell cycle activators (cyclin D1,
cyclin E and Dyrk1B), apoptosis initiator and effector proteins and EGFR dependent
proteins were analyzed in this study, the functions of other proteins associated with these
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pathways were likely modulated as well, and therefore, the cytotoxic effects of the estrone
analogs reported here may not be solely due to these proteins.

4.6

Conclusion

We report for the first time on the synthesis of a new series of estrone analogs (a hybrid of
estrone scaffold and triazole or modified triazole pharmacophores). Fz25, Fz57 and Fz200
showed good binding affinity towards EGFR kinase domain in silico and were cytotoxic
against MDA-MB-231 cells in vitro. Fz25 arrested the TNBC model within the G1 phase
whereas Fz57 and Fz200 induced cell cycle arrest within the S phase. Dyrk1B, cyclin D1
(G1 phase) and cyclin E (S phase) expression levels were downregulated by the estrone
analogs accounting for the observed G1- and S-phase cell cycle arrest. Furthermore,
morphological studies showed that the compounds induced apoptosis and modulated key
apoptotic proteins. BCl2 expression level was decreased whereas cytochrome c and Apaf1
expression levels were increased indicating mitochondrial apoptosis induction. Also,
cleaved PARP1 levels were elevated along with caspase 3 and 9 activations. EGFR and its
downstream ERK1/2 and AKT pathways were downregulated suggesting that the estrone
analogs inhibit proliferation and induce cell death. Taken together, the present study offers
initial evidence that triazole derived-estrone analogs are effective agents that can be
developed as novel therapies for TNBC.
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Figure 4.1 Molecular docking study of designed estrone analogs against EGFR binding
site (Pdb: 1M17). Scatter plot of compounds consensus scores generated by VIDA
application.
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Figure 4.2. 3D visual representation of reference drug, erlotinib, docked against EGFR
binding site. There is hydrogen bonding from the pyrimidine-N2 of erlotinib towards
MET769A of 1M17 binding site.
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Figure 4.3 3D visual representation of Fz25 docked against EGFR binding site. The
dashed green lines show hydrogen bonding from the triazole, N1, N2 and N3, and hydroxy
group towards ASP831A, GLU738A and THR766A, respectively of 1M17.
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Figure 4.4. 3D visual representation of Fz200 docked against EGFR binding site. The
dashed green lines show hydrogen bonding from the triazole-N1 and N2 of Fz200 towards
CYS773A of 1M17 binding site.
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Figure 4.5 3D visual representation of Fz57 docked against EGFR binding site. Fz57
shows hydrogen bonding from the triazole-N1 towards CYS773A of 1M17 binding site.
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Table 4.1 Cytotoxic effects of estrone analogs against breast cancer cells.

IC50 (µM)
Compound

MDA-MB-231 cells

MCF-7 cells

Sorafenib

10.62 ± 0.02

12.21 ± 0.96

Fz 25

8.12 ± 0.85

8.13 ± 0.15

Fz 200

10.86 ± 0.69

20.86 ± 3.16

Fz 57

21.18 ± 0.23

11.94 ± 0.19

Fz 60

28.88 ± 0.86

25.21 ± 0.87

Fz 300

14.95 ± 1.85

18.38 ± 1.97

Fz 400

21.21 ± 0.76

21.49 ± 0.95

Fz 100

>100

>100

Fz 516

>100

>100

Fz 313

>100

>100

Fz 600

>100

>100

Fz 518

>100

>100

Fz 60

>100

>100

Fz 552

> 100

> 100

Fz 550

50.00 ± 0.20

100.00 ± 0.00

Fz 514

> 100 ± 0

> 100 ± 0

Estrone

80.07 ± 0.85

>100

In vitro cytotoxic activities (IC50, μM) of estrone analogs against breast cancer cells. IC50
values were calculated by non-linear regression analysis. Values represent Mean ± SD of
the quadruplicate experiment (n = 4).
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DMSO

Fz200

Fz25

Fz57

Sorafenib

Figure 4.6 Morphological changes in of MDA-MB-231 cells after treatment with 0.05%
DMSO, Fz25, Fz57, Fz200 and sorafenib. Images were acquired with ×4 objective lens of
Evos XL cell imaging system (ThermoFisher Scientific), scale bar = 1000 µm.
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Figure 4.7 Initial apoptosis induction in MDA-MB-231 cells assayed by Annexin V. Cells
were treated with IC50, 2IC50 and 3IC50 of estrone analogs or positive control,
camptothecin. The cells were then incubated with Annexin V reagent and luminescence
measured by a luminometer. At least two independent experiments were performed in
triplicate. (A) Quantification of apoptotic cells after 6 hrs of incubation of drug treatments
(B). Quantification of apoptotic cells after 48 hrs of incubation with the compounds.
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Figure 4.8 Apoptotic cells observed by Hoechst 33342 staining. MDA-MB-231 cells were treated
with 0.05% DMSO (A), IC50 of estrone analogs (B-Fz25, C-Fz57 and D-Fz200) or positive control,
sorafenib (E). Apoptotic cells exhibited chromatin condensation and nuclear fragmentation.
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Figure 4.9 Expression levels of cytosolic cytochrome C and APAF1 in MDA-MB-231 cells

assayed by In-Cell Western (ICW). After treatment with estrone analogs in a dosedependent manner, fixed cells were incubated with specific antibodies for each protein.
The cells were washed and incubated with DyLight conjugated (680 nm) detection
antibodies, and plates scanned with LICOR Odyssey® Fc imaging system to measure the
levels of APAF1, cytochrome C and GAPDH. Quantitation of proteins was completed
using scanned images from Fiji software, and expression levels of APAF1 and cytochrome
C normalized to GAPDH. At least two independent experiments were performed. (A) Fz25
(B) Fz57 and (C) Fz200.
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Figure 4.10 In-Cell Western quantification of apoptosis-associated proteins. After
treatment with estrone analogs in a dose-dependent manner, fixed cells were incubated
with specific antibodies for each protein. The cells were washed and incubated with
DyLight conjugated (680 nm) detection antibodies, and plates scanned with LICOR
Odyssey® Fc imaging system to measure the levels of each protein. Quantitation of
proteins was completed using scanned images from Fiji software, and expression levels of
the proteins normalized to GAPDH. At least two independent experiments were performed.
(A) Fz25 (B) Fz57 and (C) Fz200
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Figure 4.11 Estrone analogs exposure resulted in G1- or S-phase cell cycle arrest. MDAMB-231 cells were treated with IC50 values of estrone analogs and analyzed after 48 hrs
by flow cytometry. Distribution of cells in distinct phases of the cell cycle. Fz25 and
sorafenib, positive control, showed G0/G1 phase cell cycle arrest compared to the negative
control, DMSO. Fz57 and Fz200, on the other hand, showed an S-phase cell cycle arrest.
The bar graphs show Mean ± SD of the percentages of MDA-MB-231 cells in the indicated
phases of the cell cycle (G0/G1, S and G2/ M). At least three independent experiments were
performed. *p < 0.05, **p < 0.01, ***p < 0.001 significant differences in cell cycle arrest
compared to DMSO control.
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Figure 4.12 Effects on G1- or S-phase cell cycle regulators after treatment of MDA-MB231 cells with estrone analogs. Cells were treated for indicated concentrations, fixed and
analyzed by ICW. Wells were incubated with appropriate primary antibodies and
subsequently incubated with appropriate DyLight conjugated (680 or 800 nm) detection
antibodies. LICOR Odyssey® Fc imaging system was used to scan wells. Protein
quantification was completed using scanned images from Fiji software, and expression
levels of the proteins normalized to GAPDH. Bar graphs are means ± SD from at least two
independent experiments. (A) Fz25 (B) Fz57 and (C) Fz200.
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Figure 4.13 Effect of estrone analogs treatment on EGFR and downstream ERK1/2
effector molecules in MDA-MB-231 cells. Cells were treated for indicated concentrations,
fixed and analyzed by ICW. Wells were incubated with appropriate primary antibodies and
subsequently incubated with appropriate DyLight conjugated (680 or 800 nm) detection
antibodies. LICOR Odyssey® Fc imaging system was used to scan wells. Protein
quantification was completed using scanned images from Fiji software, and expression
levels of the proteins normalized to GAPDH. Bar graphs are means ± SD from at least two
independent experiments. (A) Fz25 (B) Fz57 and (C) Fz200.
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Figure 4.14 Effect of estrone analogs treatment on Akt pathway proteins in MDA-MB231 cells. Cells were treated for indicated concentrations, fixed and analyzed by ICW.
Wells were incubated with appropriate primary antibodies and subsequently incubated with
appropriate DyLight conjugated (680 or 800 nm) detection antibodies. LICOR Odyssey®
Fc imaging system was used to scan wells. Protein quantification was completed using
scanned images from Fiji software, and expression levels of the proteins normalized to
GAPDH. Bar graphs are means ± SD from at least two independent experiments. (A) Fz25
(B) Fz57 and (C) Fz200.
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Chapter 5

General Conclusions and Recommendation

In conclusion, we have demonstrated that a new series of estrone analogs have been
synthesized and have been investigated against EGFR-dependent cancers. Using molecular
docking studies, these analogs were first designed, the receptor of interest, the EGFR
kinase domain was prepared, and the docking simulations carried out to identify hits. The
hit compounds showed key interactions like hydrogen bonding, cation-π interaction, and
other hydrophobic interactions towards amino acid residues within the EGFR kinase
domain. These compounds were synthesized, and their biological activity evaluated. The
cytotoxic effects of the novel analogs were established and the mechanisms of action
underlying the cytotoxic effect were elucidated (inhibition of cell proliferation and /or
induction of cell death). Cell cycle arrest, modulation of EGFR, and its downstream MAPK
and AKT signaling were investigated as the mechanisms underlying inhibition of cell
proliferation. The mitochondrial apoptosis pathway was investigated as the mechanism
responsible for cell death.

In our first study where estrone hybrids with modified cucurbitacin size chains (MMA
series) were tested against NCIH226 (model for EGFR wild-type NSCLC), we came to the
conclusions that novel estrone analogs (a hybrid of modified cucs pharmacophore and
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estrone-base scaffold) were potent and bind better to wild-type EGFR ATP binding site in
silico. Among these, MMA307 and MMA320 significantly inhibited the proliferation of
NCIH226 cells in vitro. This effect could be ascribed in part to the suppression of EGFR
and its downstream ERK1/2 signaling pathway and to the arrest of G1 phase the cell cycle.
In our second study, we demonstrated that some MMA series of compounds were very
effective against the TNBC model MDA-MB-468. Molecular docking studies revealed that
MMA307 and MMA321 were very potent against EGFR kinase domain (pdb code: 1M17)
in silico. Moreover, this study revealed that MMA307 and MMA321 induced
mitochondrial apoptosis, arrested G1 phase of the cell cycle, suppressed activated EGFR
and its downstream MAPK and AKT signaling.

Finally, we showed that the estrone analogs with modified triazole pharmacophores (Fz
series) were potent against the TNBC model MDA-MB-231. Fz25 showed better binding
and potency in silico towards EGFR kinase domain. This compound induced mitochondrial
apoptosis, arrested G1 phase of the cell cycle, and suppressed activated EGFR and its
downstream MAPK and AKT signaling.

To the best of our knowledge, there was no report about estrone analogs with modified
cucurbitacin or triazole pharmacophores having potential therapeutic applications in
treating NSCLC and TNBC cancers which possess a high risk of brain metastasis. The
results presented herein provide novel information on such lead compounds. Taken
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together, the present results suggest that estrone analogs may be the next generation of
small molecules anti-EGFR targeting multiple types of EGFR-dependent cancers.

Further studies are needed to progress these compounds into clinical trials. Monolayer cell
culture screens are often the initially applied methods for cytotoxic studies. Even though
these procedures represent a fast and convenient approach to determine drug bioactivity,
they do not mimic the heterogeneity of three-dimensional growth in vivo. As such, the
toxicity and predictions of off-target effects of small molecules cannot be properly
evaluated by 2D monolayer cellular screens. On the contrary, in vivo and primary in vitro
3D tumor models used in preclinical drug development are more closely related to the
three-dimensional growth of a patients tumor in clinical settings. Moreover, these tumor
models are better at predicting clinical effects when compared with in vitro 2D tumor
models because several parameters including pharmacokinetics, efficacy and safety of lead
candidates are monitored in parallel. We propose that these compounds should first be
tested in 3D models of NSCLC and TNBC primary tumors to establish their dosing and
toxicity. Secondly, the compounds physicochemical profiles should be predicted in vitro.
Finally, these compounds should be tested in appropriate preclinical settings. Based on the
compound’s toxicity profiles and pharmacokinetics, a lead optimization step may be
conducted to improve their efficacy and safety be performing clinical trial studies.
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Figure 5.1 Graphical summary of design, synthesis and biological evaluation of estrone
analogs. Estrone analogs were designed and screened with CAMM to identify hits. The
hits were synthesized using estrone as a starting material to obtain MMA or Fz series of
compounds. The cytotoxic effects of the compounds were tested and mechanisms of
induction of apoptosis and/or inhibition of cell proliferation elucidated.

